












Neuroendokrine Effekte der endokrinen Disruptoren 
Vinclozolin und Equol  












zur Erlangung des Doktorgrades 
der Mathematisch–Naturwissenschaftlichen Fakultät 


































Neuroendocrine effects of the endocrine disruptors 












in partial fulfillment of the requirements 
for the doctoral degree “Ph.D.” 
in the Graduate Program 
Center for Systems Neuroscience 














































Members of Thesis Defense Committee: 
 
Thesis doctoral committee: Prof. Dr. Stefan Treue 
Prof. Dr. Hannelore Ehrenreich 
Prof. Dr. Hubertus Jarry 
 
Thesis defense referees: Prof. Dr. Ralf Heinrich 
    Prof. Dr. Rüdiger Hardeland 
    Prof. Dr. Detlef Doenecke 
 





STATEMENT OF ORIGINALITY: 
 
I declare that this thesis is my own work and contains nothing which is the outcome of work 
done in collaboration with others, except as a specified in the text and Acknowledgements. 
The thesis submitted has been written independently with no other sources and aids than 






























































































TABLE OF CONTENTS 
 
 
      Page 
 
1. INTRODUCTION ………….………………………………….…………………………………...……. 1 
     1.1. Background………………………………………………………………………………………… 1 
     1.2. Estrogenic endocrine disruption by Equol………………………………………………………. 2 
     1.3. Antiandrogenic endocrine disruption by Vinclozolin…………………………………………… 4 
     1.4. New endocrine features of EQ and VZ………………………………………………………….. 6 
     1.5. Endocrine disruption and the brain……………………………………………………………… 7 
     1.6. Potential action sites of VZ and EQ within the HPG axis of male rats………………………. 8 
     1.7. Hypothesis, objectives, and experimental paradigm………….………………………………. 11 
2. MATERIALS AND METHODS……………………………………………………………………….... 13 
     2.1. Test substances…………………………………………………………………………...…….… 13 
     2.2. Animals and husbandry ………………………………………………….…………………...….. 14 
     2.3. Animals and treatments……………………………………………………...……….…………... 14 
            2.3.1. In vivo experiment 1: Neuroendocrine effects of VZ in adult male rats….…………… 14 
            2.3.2. In vivo experiment 2: Neuroendocrine effects of EQ in adult male rats……………… 15 
     2.4. Vaginal cytology…………………………………………………………...…………….………… 16 
     2.5. Mating behavioral testing procedure…………………………………………………………….. 18 
     2.6. Necropsy, collection of target organs, and measurement of organ weights………………… 18 
     2.7. Serum hormone analysis……………………………………………………………………...….. 18 
     2.8. Serum metabolic parameter analysis……………………………………………………...……. 19 
     2.9. HPLC analysis for serum levels of the test substances………………………………..……… 19 
     2.10. Microdissection of brain areas……………………………………………………………..…... 20 
     2.11. Tissue homogenization and RNA extraction…………………………….………………...….. 22 
     2.12. Gene expression analysis………………………………………………….……………...……. 22 
              2.12.1. Reverse transcription...…………………………………………………………………. 23 
              2.12.2. Quantitative TaqMan Real-time PCR Assay………………………………………... 23 
                        2.12.2.1. Set up conditions for the quantitative TaqMan real-time PCR assay...… 24 
                        2.12.2.2. Standard curves……………………………………………………………….. 26 
              2.12.3. Statistical analysis………………………………………………………………………. 27 
     2.13. Histological and immunocytochemical analyses……………………………………………… 27 
              2.13.1. Histological procedure………………………………………………………………….. 27 
              2.13.2. Hematoxylin and Eosin (H&E) staining technique…………………………………… 28 
              2.13.3. Immunolocalization of ERα in the pituitary…………………………………………… 29 
              2.13.4 Quantitative analysis of the positive immunostained cells and photography……... 31 
3. RESULTS………………………………………………………………………………………………… 32 
     3.1. In vivo Experiment 1: Neuroendocrine effects of VZ in adult male rats……………………... 32 
            3.1.1. Clinical signs, body weight gain, and food consumption…...………………………….. 32 
            3.1.2. Daily intake and serum concentration of VZ…………………………………………….. 32 
            3.1.3. Relative weights of reproductive and accessory sex organs………………………….. 32 
            3.1.4. Serum levels of reproductive and thyroid hormones…………………………………… 33 
            3.1.5. Serum metabolic parameter levels……………………………………………….…….... 34 
            3.1.6. mRNA expression analysis in the pituitary……………………………………………… 34 
            3.1.7. mRNA expression analysis in the MBH/ME………………………………………….…. 35 
CONTENTS 
 
            3.1.8. mRNA expression analysis in the MPOA/AH………………………………………….... 36 
            3.1.9. mRNA expression analysis in the striatum…………………………………………….... 36 
            3.1.10. mRNA expression analysis in the hippocampus…………………………………...…. 37 
            3.1.11. mRNA expression analysis in the ventral prostate………………..……………….…. 37 
            3.1.12. mRNA expression analysis in the seminal vesicles..…………………………………. 38 
            3.1.13. mRNA expression analysis in the epididymis………………………………………….  38 
     3.2. In vivo experiment 2: Neuroendocrine effects of EQ in adult male rats……………..………. 40 
            3.2.1. Clinical signs, body weight gain, and food consumption………………………...…….. 40 
            3.2.2. Daily intake and serum concentrations of the test substances……………………….. 40 
            3.2.3. Effects of the test substances on expression of male mating behavior……………… 41 
            3.2.4. Relative weights of reproductive and accessory sex organs …………………………. 44 
            3.2.5. Serum levels of reproductive and thyroid hormones…………………………………… 44 
            3.2.6. Serum concentrations of metabolic parameters………………………………………... 44 
            3.2.7. mRNA expression analysis in the pituitary……………………………………………… 46 
            3.2.8. mRNA expression analysis in the MBH/ME…………………………………………….. 48 
            3.2.9. mRNA expression analysis in the MPOA/AH………………………………….............. 48 
            3.2.10. mRNA expression analysis in the amygdala and hippocampus…………………….. 49 
            3.2.11. mRNA expression analysis in the ventral prostate……………………………………. 49 
            3.2.12. ERα immunolocalization in the pituitary……………………………………………….. 50 
4. DISCUSSION…………………………………………………………………………………………..... 54 
     4.1. In vivo Experiment 1: Neuroendocrine effects of VZ in adult male rats……………………... 54 
            4.1.1. Achieved dosage of VZ after 5 days oral application…………………………………... 54 
            4.1.2. Effects of VZ on the reproductive organ weights and hormone levels……………….. 54 
            4.1.3. Effects of VZ on the hypothalamic GnRH pulse generator……………………………. 55 
            4.1.4. Effects of VZ on the extrahypothalamic regions………………………………………... 56 
            4.1.5. Effects of VZ on the pituitary function……………………………………………………. 56 
            4.1.6. Effects of VZ on the thyroid hormone homeostasis……………………………………. 57 
            4.1.7. Effects of VZ on the reproductive and accessory sex organs………………………… 57 
     4.2. In vivo Experiment 2: Neuroendocrine effects of EQ in adult male rats…………..………… 58 
            4.2.1. Effects of EQ on mating behavior in the male rat………………………………………. 58 
            4.2.2. Effects of EQ on the reproductive organ weights and hormone levels………………. 59 
            4.2.3. Effects of EQ on the hypothalamic GnRH pulse generator……………………………. 60 
            4.2.4. Effects of EQ on the extrahypothalamic structures…………………………………….. 60 
            4.2.5. Effects of EQ on the pituitary function…………………………………………………… 61 
            4.2.6. Effects of EQ on thyroid hormone system………………………………………………. 62 
            4.2.7. Effects of EQ on the metabolic parameters……………………………………………... 63 
            4.2.8. Effects of EQ on the prostate function…………………………………………………… 63 
     4.3. Conclusions………………………………………………………………………….…………..… 64 
5. SUMMARY………………………………………………………………………………….…………… 65 
6. ZUSAMMENFASSUNG……………………………….…………………………………...…………... 67 
7. ACKNOWLEDGEMENTS………………………………………………...……….…………………… 70 
8. LIST OF REFERENCES………………………..……………………………………………………… 73 
9. LIST OF ABBREVIATIONS…………………………...……...……………………………………….. 84 
10. CURRICULUM VITAE…………..……………………………..………………...……………….…... 87 
 
LIST OF FIGURES 
 
LIST OF FIGURES 
 
 
     Page 
 
Figure 1 Schematic model of feedback control of the HPG axis by T or E2 (after local production 
by aromatase activity)…………………………………………………………………………… 
 
1 
Figure 2 Biodegradation of daidzein by intestinal bacteria…………………………………………….. 3 
Figure 3 A comparison of the molecular structure of equol and E2……………………………….….. 3 
Figure 4 Molecular structures of VZ and its two primary bioactive metabolites, designated M1 
and M2, which are similar to those of FLUT and its metabolite, hydroxyflutamide…….... 
 
5 
Figure 5 Schematic diagram of the in vivo model to investigate the possible endocrine-disrupting 
effects of VZ and EQ on the brain and its neuroendocrine function like regulation of the 




Figure 6 The chemical structure of equol and its fact sheet…………………………………………… 13 
Figure 7 The structural formula of vinclozolin and its descriptions…………………………………… 13 
Figure 8 The molecular structure of flutamide and its properties……………………………………... 14 
Figure 9 Time line of the study design of the in vivo experiment 1………………………………….... 15 
Figure 10 Time line of the experimental design of the in vivo experiment 2………………………….. 16 
Figure 11 Photomicrographs of the native vaginal smears collected from female rats at proestrus 
(A); estrus (B); diestrus 1 (C); and diestrus 2 (D)……………………………………………. 
 
17 
Figure 12 Behavioral rhythms of the rat's estrus cycle………………………………………………….. 17 
Figure 13 Microdissection of the MPOA/AH, striatum, and amygdala…………………………………. 20 
Figure 14 Microdissection of the hippocampus…………………………………………………………... 21 
Figure 15 Microdissection of the MBH/ME………………………………………………………………... 21 
Figure 16 Mean final body weights and average daily food intake of adult male rats treated with 
VZ for 5 days………………………………………………………………………….…………. 
 
32 




Figure 18 Relative weights of liver, testes, ventral prostate, seminal vesicles, and epididymides…. 33 
Figure 19 Mean serum levels of LH, T, TSH, total T4 and T3…………………………………………… 34 




Figure 21 Relative mRNA expression levels of ERα, ERβ, AR, TERP-1 and -2 in the pituitary……. 35 
Figure 22 Relative mRNA expression levels of GnRHR, LHβ, α-subunit, and TSHβ in the pituitary. 35 
Figure 23 Relative mRNA expression levels of ERα, ERβ, AR, and GnRHR in the MBH/ME……… 36 
Figure 24 Relative mRNA expression levels of ERα, ERβ, AR, and GnRH in the MPOA/AH……… 36 
Figure 25 Relative mRNA expression levels of ERα, ERβ, and AR in the striatum………………….. 37 
Figure 26 Relative mRNA expression levels of ERα, ERβ, and AR in the hippocampus…………… 37 
Figure 27 Relative mRNA expression levels of ERα, ERβ, and AR in the ventral prostate…………. 38 
Figure 28 Relative mRNA expression levels of ERα, ERβ, and AR in the seminal vesicles………... 38 
Figure 29 Relative mRNA expression levels of ERα, ERβ, and AR in the epididymis………………. 39 
Figure 30 Effects of the 5-day oral administration with either EQ at low and high doses, or FLUT 





Figure 31 Mean serum levels of EQ and FLUT…………………………………………………………... 41 
Figure 32 Two representative photomicrographs showing the presence of spermatozoa in vaginal 
lavages of sexually receptive female rats after mating with the vehicle-treated males (n 




Figure 33 Two representative photomicrographs showing the absence of spermatozoa in vaginal 
lavages of sexually receptive females after mating with the FLUT-exposed male rats (n 




Figure 34 Two representative photomicrographs of positive vaginal lavages of sexually receptive 





Figure 35 Two representaive photomicrographs of positive vaginal lavages of sexually receptive 





Figure 36 Two representative photomicrographs showing the presence of spermatozoa in vaginal 
lavages of sexually receptive female rats after mating with the males s.c. injected with 




Figure 37 Relative weights of testes, epididymides, ventral prostate, seminal vesicles, and liver…. 45 
Figure 38 Mean serum concentrations of LH, PRL, T, and DHT……………………………………….. 45 
Figure 39 Mean serum levels of TSH, total T4 and T3…………………………………………………… 46 
Figure 40 Mean serum levels of cholesterol, triglycerides, high- and low-density lipoproteins……... 46 
Figure 41 Relative mRNA expression levels of ERα, ERβ, AR, TERP-1 and -2 (A) and GnRHR, 
LHβ, α-subunit, and TSHβ (B) in the pituitary………………………………………………... 
 
47 
Figure 42 Relative mRNA expression levels of ERα, ERβ, AR, and GnRHR in the MBH/ME……… 48 
LIST OF FIGURES 
 
Figure 43 Relative mRNA expression levels of ERα, ERβ, AR, and GnRH in the MPOA/AH……… 48 




Figure 45 Relative mRNA expression levels of ERα, ERβ, and AR in the ventral prostate………… 50 




Figure 47 Representative sections demonstrating the immunolocalization of ERα in the pituitary of 
adult male rats treated by gavage for 5 days with either vehicle olive oil (A;a), EQ at low 




Figure 48 Relative percentages of the positive ERα immunoreactive cells in the anterior pituitary... 52 
 
LIST OF TABLES 
LIST OF TABLES 
 
 
          Page 
 
Table 1 Potential action sites of VZ and EQ within the HPG axis of male rats and endpoints 
measured in the present study…………………………………………………………………. 
 
10 








Table 4 Components of 2x ABI TaqMan™ Universal PCR Master Mix.…………………...………… 24 
Table 5 Preparation of a 25 µl PCR Reaction Mix…………………………………………..………… 25 
Table 6 Optimized concentrations of the corresponding TaqMan primer pairs and probe of each 
gene investigated in the present study…………………………………………………….….. 
 
26 




Table 8 Step-by-step procedure of the H&E staining method………………………...……………… 29 
Table 9 A compilation of effects of VZ on the brain and the intact HPG axis after a 5-day oral 
treatment in adult male rats…………………………………………………………………….. 
 
39 
Table 10 Effects of a 5-day oral administration of adult male rats with either EQ low and high 
doses, or FLUT on male mating behavior and female pregnancy outcome……………… 
 
41 
Table 11 Mating behavior of adult male rats in response to 5 days after cessation with FLUT 
treatment and pregnancy rate of the mated females…………………..……………………. 
 
44 
Table 12 An overview of effects of EQ compared to that of FLUT on the brain and its 














The endogenous gonadal steroids, estradiol (E2) and testosterone (T), play pivotal roles in 
the differentiation, development, and maturation of the brain and its neuroendocrine function 
like regulation of the hypothalamo-pituitary-gonadal (HPG) axis (Kalra and Kalra, 1983; 
Mooradian et al., 1987; Levine et al., 1991; McEwen and Alves, 1999). The HPG axis 
comprises gonadotropin-releasing hormone (GnRH) neurons in the hypothalamus, the 
luteinizing hormone (LH) and follicle-stimulating hormone (FSH) producing gonadotropes in 
the pituitary and, in male mammalians, the T-producing Leydig cells of the testis (Fig. 1). T 
can directly affect the release of GnRH or LH/FSH or indirectly of its conversion to E2 by the 
enzyme aromatase which is expressed in the brain and pituitary (Abdelgadir et al., 1994; 




Figure 1.  Schematic model of feedback control of the HPG axis by T or E2 (after local production by 
aromatase activity). NR = nuclear receptors. (adapted from Rochira et al., 2006). 
 
The mechanisms of action of E2 and T are mediated through their specific nuclear receptors 
(NR) termed as estrogen receptors (ERs), subtypes α (ERα) and β (ERβ), and androgen 
receptor (AR), respectively. The two ERs are not isoforms of each other, but are the products 
of distinct genes located on separate chromosomes and differ in their C-terminal ligand-
binding domains, suggesting that they could have different effects in some target tissues 




























and are intracellular ligand-activated transcription factors. After binding the ligand, receptor 
monomers dimerize and the hormone-receptor complex is translocated into the nucleus 
where it binds to the specific promoter sequences designated estrogen response element 
(ERE) or androgen response element (ARE). Upon binding to the response elements, a 
number of coregulators are recruited to activate transcription of various genes relevant for 
the regulation of estrogenic or androgenic physiological actions (for reviews see Nilsson et 
al., 2001; Gelmann, 2002).  
 
There is increasing evidence that besides the endogenous ligands E2 or T numerous 
anthropogenic chemicals and natural plant-derived products directly interact with ERs and/or 
AR. Thus, it is conceivable that any compound which is capable to bind to ERs and AR may 
alter the functions of those systems which are physiologically regulated by endogenous 
gonadal steroids like development or reproductive function. Those compounds are classified 
as ‘Endocrine Disruptors’ (EDs) (Guillette and Gunderson, 2001; Lintelmann et al., 2003; 
Acerini and Hughes, 2006). 
 
EDs can be divided into three major classes: (1) antiandrogens, primarily pesticides, that are 
antagonists of the AR function; (2) industrial chemicals with estrogen-like structures that act 
as agonists or partial agonist for ERs (= xenoestrogens); and (3) plant-derived polyphenolic 
non-steroidal compounds with estrogen-like structure and actions (= phytoestrogens) (for 
review see Lintelmann et al., 2003). Several possibilities of the mechanisms of EDs action 
have been proposed: (a) mimicking the normal activities of endogenous hormones; (b) 
antagonizing the normal activities of endogenous hormones; (c) disruption of the 
biosynthesis and metabolism of endogenous hormones; and (d) disruption of the 
biosynthesis and metabolism of endogenous hormone receptors (for reviews see 
Sonnenschein and Soto, 1998; Lintelmann et al., 2003).  
 
In the following, two examples of EDs with either estrogenic or antiandrogenic activity will be 
introduced. 
 
1.2. Estrogenic endocrine disruption by Equol 
 
The first described estrogenic EDs are isoflavones isolated from soy beans. These EDs were 
named ‘’Phytoestrogens’’. The two major isoflavones in soy beans are genistein and 
daidzein. Both phytoestrogens can bind to ERα and ERβ with a slight preference to ERβ 
(Muthyala et al., 2004; Casanova et al., 1999). In vivo, isoflavones are metabolized by gut 
bacteria thereby being inactivated or being converted to still endocrine active or even more 
potent metabolites (Setchell et al., 1984; 1999; Bowey et al., 2003). For example, the soy-




further converted to either O-desmethylangolensin (O-DMA) (5-20%) or equol (EQ) (70%) 
(Chang and Nair, 1995; Bowey et al., 2003; Decroos et al., 2005) (Fig. 2). While O-DMA is 
inactive with regard to estrogenic properties, EQ is a strong estrogen which finally mediates 
the well known estrogenic effects of soy in mammalians (Chang et al., 1995; Schmitt et al., 




Figure 2.  Biodegradation of daidzein by intestinal bacteria (modified from Decroos et al., 2005). 
 
EQ (3, 4-dihydro-3-(4-hydroxyphenyl)-2H-1-benzopyran-7-ol; C15H14O3) has a molecular 
structure similar to E2. As shown in Figure 3, the distance and orientation of the phenolic 
(box A) and hydroxyl (box B) groups of EQ is similar to those of the phenolic and hydroxyl 
moieties of E2. This is the minimum structural requirement for an estrogen-like acting 
molecule (Setchell et al., 1984; Jordan et al., 1984; 1985).  
 
 











Asian diets contain high amounts of soy. It is known that in Asian countries like Japan the 
incidence of steroid dependent cancers is significantly lower than in Western countries 
(Adlercreutz et al., 1993; Magee and Rowland, 2004). High excretion of EQ in humans 
consuming high amounts of a soy-based diet indicated that EQ may be responsible for the 
beneficial role of the dietary phytoestrogens regarding the risks of breast-, uterine-, and 
prostate cancers in these subpopulations (Setchell et al., 1984; Adlercreutz et al., 1986a; 
1986b). 
 
Recent investigations utilizing in vitro assays, including competition-binding assays with both 
ERα and ERβ proteins and transcriptional activation in mammalian cell-based assays, have 
confirmed that EQ possesses estrogenic properties mediated through ERs with greater 
affinity to bind to ERβ than to ERα (Sathyamoorthy and Wang, 1997; Mueller et al., 2004; 
Muthyala et al., 2004). Furthermore, utilizing cell proliferation assays, it was demonstrated 
that EQ stimulated in an estrogen-like manner the growth of the ERs-positive human 
mammary adenocarcinoma MCF-7 cells (Sathyamoorthy and Wang, 1997; Ju et al., 2006) 
and of human endometrial adenocarcinoma Ishikawa cells (Lehmann et al., 2005).  
 
A considerable number of published studies examining the in vivo estrogen-like effects of EQ 
indicated that EQ increased the uterine weight along with a dose-dependent increase of 
uterine epithelial proliferation and endometrial thickness in adult ovariectomized mice and 
rats, but with less extent than E2 (Tang and Adams, 1980; Selvaraj et al., 2004; Rachon et 
al., 2007c). An uterotrophic effect of EQ was also observed in the postmenopausal primate 
model of the ovariectomized monkey (Wood et al., 2006). Exposures of ovariectomized mice 
with increasing injected or dietary doses of EQ also caused dose-dependent increases in the 
vaginal epithelial thickness and vaginal cornification, corroborating its in vivo estrogenic 
effects (Selvaraj et al., 2004). In addition, dietary EQ displayed mild mammotrophic effects in 
ovariectomized monkeys (Wood et al., 2006). Chronic exposure to dietary EQ stimulated 
mRNA expression levels of estrogen-responsive genes in the uteri and pituitaries of adult 
castrated female rats (Rachon et al., 2007a; 2007c).  
 
1.3. Antiandrogenic endocrine disruption by Vinclozolin 
 
Vinclozolin (3-(3,5-dichlorophenyl)-5-ethenyl-5-methyl-2,4-oxazolidinedione; C12H9Cl2NO3) 
(VZ) is an agricultural fungicide widely used in the United States of America and the 
European Union for the control of fungal spore germination in grapes, strawberries, and 
various vegetables (Kelce et al., 1995; 1997; Gray et al., 1999). VZ is environmentally 
unstable because it can be further biotransformed by mammalian, plant and bacterial 




metabolites are 2-(3,5-dichloropheniyl)-carboxymoyl)-2-methyl-3-butenoic acid (M1) and 
3',5'-dichloro-2-hydroxy-2-methylbut-3-enanilide (M2) (Kelce et al., 1995; Sierra-Santoyo et 
al., 2004) (Fig. 4). VZ and its potent butenoic acid and enanilide metabolites have been 
found within soil, plants, wildlife, and animals exposed to VZ, and could potentially cause 
several adverse effects to human and animal health based on its structural similarity related 
to the potent and pure AR antagonistic drug flutamide (FLUT) and its hydroxylated 
metabolite, hydroxyflutamide (Kelce et al., 1995) (Fig. 4).  
 
 
Figure 4.  Molecular structures of VZ and its two primary bioactive metabolites, designated M1 and 
M2, which are similar to those of FLUT and its metabolite, hydroxyflutamide (modified from Kelce et 
al., 1994; 1995; Sierra-Santoyo et al., 2004). 
 
There is ample evidence that VZ and its two metabolites, M1 and M2, are antiandrogenic 
endocrine-active substances. Using in vitro competition-binding assays with AR protein, or 
transcriptional activation in mammalian cell-based assays, it has been shown that VZ and its 
two hydrolysis metabolites bind to both rat and human AR and competitively inhibit 
endogenous androgens for AR binding, thereby inhibiting AR for binding to the ARE, and 
subsequently antagonize AR-induced transcriptional activation (Kelce et al., 1994; Wong et 
al., 1995; Nellemann et al., 2003; Molina-Molina et al., 2006). These results clearly prove that 
in vitro VZ and its two metabolites are potent AR antagonists. In vivo VZ exposure during 
pregnancy of female rats results in a pattern of urogenital malformations in the male pups 
(Gray et al., 1994; 1999; Matsuura et al., 2005); delays the onset of puberty, growth and 
development of accessory sex organs in peripubertal male rats (Gray et al., 1994; 1999; 
Monosson et al., 1999), ultimately resulting in reduced weights of accessory sex organs and 






























































(Monosson et al., 1999; O'Connor et al., 2002; Shin et al., 2006). In adult castrated, 
testosterone-treated male rats, VZ causes alterations in the expression levels of AR-
regulated genes in the ventral prostate (Kelce et al., 1997; Nellemann et al., 2003), as well 
as of androgen-dependent testicular and pituitary specific genes in adult male rats (Kubota et 
al., 2003). Thus, VZ and its metabolites first compete with endogenous androgens for binding 
to AR, resulting in inhibition of AR-binding to ARE and subsequent AR-induced 
transcriptional activation both in vitro and in vivo.  
 
1.4. New endocrine features of EQ and VZ 
 
VZ has been identified as a mixed antagonist or agonists for the AR, depending on the ligand 
binding affinity, concentration, and the presence of the natural androgens (Wong et al., 1995; 
Wilson et al., 2002; Korner et al., 2004). The overall antiandrogenic effects of VZ on the 
pattern of urogenital malformations, or alterations in accessory sex organ weights and serum 
reproductive hormone levels in adult male rats was nearly identical to that reported for the 
well-known antiandrogen FLUT (Gray et al., 1994; Nellemann et al., 2003; Yu et al., 2004). 
Recently, VZ and its two biologically active metabolites have attracted attention because in 
vitro they interact directly with both ERα and ERβ, with the greater affinity for ERα (Scippo et 
al., 2004; Molina-Molina et al., 2006). These data point to the possibility that the in vitro 
observed ERs agonistic action of VZ may contribute to its endocrine-disrupting properties in 
vivo. The observation of an estrogenic activity of VZ, formerly classified as a pure 
antiandrogen, raised the question whether EDs only interact with one type of nuclear 
receptors. In other words, does an estrogenic ED exert also antiandrogenic activity, i.e. is 
there a promiscuity regarding receptor selectivity? 
 
Indeed, there is increasing evidence that those additional endocrine features are 
characteristic for EDs. It has been shown recently that EQ in addition to its estrogen-like 
activity has also antiandrogenic properties because in vitro it inhibits proliferation of human 
benign and malignant prostatic epithelial cells at concentrations typically found in the serum 
of men consuming a soy-rich diet (Hedlund et al., 2003). Lund et al. (2004) reported that the 
in vitro antiandrogenic properties of EQ are unique since EQ does not bind to the AR, but 
potently binds DHT (but not T), and thereby prevents DHT from binding to AR. Furthermore, 
subcutaneous injection of EQ (0.25 mg/kg bw/day or 0.1 mg/rat/day) to intact adult male rats 
fed ad libitum with normal rat diet for 4 days reduced weights of ventral prostate and 
epididymides without any alteration in testicular weight, and increased serum LH without any 







1.5. Endocrine disruption and the brain 
 
The deleterious effects of EDs on development and functions of sex steroid-regulated tissues 
have been investigated thoroughly in peripheral organs in particular the urogenital system in 
both female and male animals. However, surprisingly little efforts have been made to 
investigate the pharmacological actions of EDs in the central nervous system (CNS) in spite 
of the fact that virtually any brain area is sex steroid hormone receptive. Thus, it is clearly 
apparent that EDs may have the potential to alter brain function like neuroendocrine activity.  
 
FLUT (2-Methyl-N-(4-nitro-3-(trifluoro-methyl) phenyl) propanamide; C11H11F3N2O3) (Fig. 4) is 
well characterized as potent and pure nonsteroidal AR antagonist possessing high specificity 
for AR without cross-reactions with any other of sex steroid receptors (Simard et al., 1986; 
Laws et al., 1996; Roy et al., 2004). FLUT has been used therapeutically as an oral 
antiandrogenic drug primarily to treat prostate cancer or hyperplasia (Labrie, 1993; Singh et 
al., 2000; Gao et al., 2006), and is widely used as an positive AR antagonist in numerous 
recent investigations on the role of EDs in modulating androgen metabolism and function 
during male reproductive development (Kelce et al., 1997; Yu et al., 2004; Kang et al., 2004).  
 
FLUT is metabolized within the gastric tract to its potent hydrolysis metabolite, 
hydroxyflutamide (Fig. 4) (Neri et al., 1989; Gao et al., 2006). FLUT and its metabolite 
compete with endogenous androgens for binding to AR, inhibit AR-ARE binding, and alter 
androgen-induced transcriptional activation in vitro (McGinnis and Mirth, 1986; Wong et al., 
1995; Sohoni and Sumpter, 1998). In vivo perinatal exposure of pregnant rat dams with 
FLUT throughout gestation caused a pattern of malformations of the urogenital tract, 
decreased weights of ventral prostate, seminal vesicles and testes, increased serum levels 
of LH, FSH and T in the male rat pubs (Kassim et al., 1997; Miyata et al., 2002; 2003; Goto 
et al., 2004; Foster and Harris, 2005). Postnatal exposure of intact adult male rats with FLUT 
resulted in increased serum levels of LH, FSH, T, DHT and E2, decreased weights of ventral 
prostate, seminal vesicles, and epididymides (O'Connor et al., 1998a; 2002; Toyoda et al., 
2000, Shin et al., 2002), and altered androgen-dependent gene expression in the testis, 
ventral prostate and pituitary in the adult male rat (Ohsako et al., 2003; Vinggaard et al., 
2005). These data indicated that FLUT disrupts the function of the HPG axis of male rats in a 
typical pattern of an AR antagonist, i.e. decreases weights of androgen-dependent male 
accessory reproductive tissues and increases levels of serum reproductive hormones, and 
alters AR-regulated gene expression in the androgen-dependent organs.  
 
Subcutaneous injection or local implants of FLUT as well as its metabolite into various brain 
regions including the preoptic-hypothalamus-limbic continuum of the adult castrated-T-




effectively inhibit restoration of male sexual behavior (Sodersten et al., 1975; McGinnis and 
Mirth, 1986; McGinnis et al., 1996; 2002). Taken together, these data document an 
endocrine disrupting action of FLUT both in the CNS and its neuroendocrine activity. 
Surprisingly, while the neuroendocrine effects of the synthetic antiandrogenic drug FLUT are 
well characterized, with regard to EDs there is a clear lack of data on brain function like 
neuroendocrine regulation of the HPG axis function in male individuals. This prompted us to 
investigate whether and how VZ and EQ affect the brain and neuroendocrine function in 
adult male rats upon an acute treatment. 
 
1.6. Potential action sites of VZ and EQ within the HPG axis of male rats 
 
As described earlier, the prerequisite of the direct endocrine-disrupting action and the initial 
step of estrogen- and androgen-mediated gene regulation, is binding of EDs to either ERs or 
AR. In male rats, both ERs and AR are expressed in the urogenital tissues including the 
prostate, seminal vesicles, and epididymides (Pelletier, 2000; Pelletier et al., 2000; Makela et 
al., 2000). In addition, in areas of the brain which have been implicated either directly or 
indirectly in neuroendocrine regulation of the HPG axis, such as the neuroendocrine 
hypothalamus, particularly the medial preoptic area/anterior hypothalamus (MPOA/AH) and 
mediobasal hypothalamus/median eminence (MBH/ME), limbic structures (i.e., 
hippocampus, amygdala) and striatum (Simerly et al., 1990; Laflamme et al., 1998; Creutz 
and Kritzer, 2004), both ERs and AR are expressed. Also in the pituitary of male rats besides 
the AR, both ERs are expressed (Shughrue et al., 1998; Pelletier, 2000). Thus, it is 
reasonable to postulate that VZ and EQ may have potential neuroendocrine effects in these 
estrogen- and androgen-responsive tissues. However, in adult male rats both ERα and ERβ 
subtypes are differentially distributed and expressed in the CNS and urogenital system 
depending on the tissue types, i.e. moderate to high expression in pituitary and epididymides 
for ERα and hypothalamic-limbic structures, prostate, and seminal vesicles for ERβ (Kuiper 
et al., 1997; Makela et al., 2000; Pelletier, 2000), suggesting that they could have different 
and specific functions in some target tissues in response to estrogen or estrogenic 
compound exposure. Taken together, these data prompt us in the present study to observe 
both ERα and ERβ, and AR expression in the selected brain regions (MPOA/AH, MBH/ME, 
hippocampus, amygdala, striatum), pituitary, and male accessory sex glands (prostate, 
seminal vesicles, epididymides). 
 
Regulation of the HPG axis in the rats depends upon the hypothalamic GnRH pulse 
generator. This neuronal network causes pulsatile release of GnRH at the ME of MBH into 
hypophyseal portal vessels, and subsequently regulates pulsatile pituitary gonadotropin LH 




reproductive function and development (Kalra and Kalra et al., 1983; Levine et al.,1991; 
Wuttke et al., 1996). It is well known that in the rat, cell bodies of GnRH neurons are located 
within the MPOA/AH, while their axons terminate in the MBH/ME. Since GnRH secretion 
cannot be measured directly, GnRH mRNA levels were determined as an indirect measure of 
secretion of the releasing factor (Jarry et al., 2004). GnRH binds with high affinity to the 
GnRH receptor (GnRHR) on the cell surface of gonadotropes, thereby activating the 
intracellular signal transduction pathway to affect both synthesis and pulsatile release of 
gonadotropins. The pituitary responsiveness to GnRH pulses correlates directly with the level 
of GnRHR expression (Norwitz et al., 1999). Therefore, in the present study, the MPOA/AH 
GnRH and the MBH/ME as well as pituitary GnRHR mRNA levels were examined.  
 
In the pituitary, besides measurement of the ERs and AR expression, levels of the pituitary-
specific, truncated isoform of rat ERα (TERP-1 and -2) mRNA expression (Friend et al., 
1997; Mitchner et al., 1998; Tena-Sempere et al., 2001a) which are positively regulated by 
E2, but not T, were also examined in the present study. In addition, expression levels of the 
α- and β-subunit of LH which are known E2-regulated genes in the pituitary were also 
analyzed. Changes in levels of TERP-1/-2, LHβ and α-subunit mRNA expression, and serum 
prolactin (PRL) can be used as surrogate markers for estrogenic actions of the test 
compounds in the rat pituitary (Jarry et al., 2004; Klammer et al., 2005; Rachon et al., 
2007a). 
 
The classical endpoints for detection of putative antiandrogenic EDs suggested by the 
several international organizations like the OECD (Organization for Economic Cooperation 
Development) and the United States Environmental Protection Agency (U.S. EPA) task force 
on the EDs (EDSTAC), such as wet weights at autopsy of the androgen-dependent male 
accessory sex organs (prostate, seminal vesicles, and epididymides) and serum 
concentrations of reproductive hormones [LH, T, dihydrotestosterone (DHT)] were also 
included to gain a better understanding of ongoing neuroendocrine effects of VZ and EQ on 
the intact HPG axis in adult male rats.  
 
An other important target of the neuroendocrine-disrupting activity of several EDs is the 
thyroid gland as the pituitary-thyroid axis is also regulated by E2 action. Thyroid hormones 
(TH), i.e. thyroxine (T4) and triiodothyronine (T3), are major regulators of multiple 
physiological processes during development, growth, differentiation, and metabolism. 
Alterations in TH levels affect developing organisms and can result in abnormalities in normal 
physiological functions of the CNS (Rivas and Naranjo, 2007; des Reis-Lunardelli et al., 
2007) and urogenital system (Arambepola et al., 1998; Rao et al., 2003). It is well 




also affect the TH system. Exposure to certain EDs, such as phytoestrogens like resveratrol 
and genistein (Bottner et al., 2006a), contaminants derived from the industrial products like 
the UV filters benzophenone 2 (BP2) (Jarry et al., 2004; Klammer et al., 2005; Schmutzler et 
al., 2007) and octyl-methoxycinnamate (OMC) (Klammer et al., 2007) and agricultural-
derived contaminants, i.e. pesticides (Kelce and Wilson, 1997; O'Connor et al., 2002), can 
significantly disturb the TH- as well as steroid hormones homeostasis in rats. However, it is 
not known whether VZ and EQ affect the TH system. Therefore, in the present study the 
neuroendocrine actions of VZ and EQ were assessed by measurement of the serum levels of 
thyroid-stimulating hormone (TSH), thyroxine (T4) and triiodothyronine (T3), and of the 
expression of the beta subunit of TSH in the pituitary as previously described (Jarry et al., 
2004; Klammer et al., 2007). 
 
In addition, known estrogen-regulated liver parameters, i.e. serum levels of cholesterol 
(CHOL), high- and low-density lipoproteins (HDL and LDL), and triglycerides (TGs) (Klammer 
et al., 2005; Schlecht et al., 2006; Rachon et al., 2007b) were also measured additionally to 
the data of liver weight which generally has to be included to assess typical toxicological 
effects of the test compounds. 
 
The potential action sites and endpoint parameters selected for the present investigation of 
the neuroendocrine-disrupting effects of VZ and EQ on the function of the HPG axis in adult 
male rats are summarized in Table 1. 
 
Table 1  Potential action sites of VZ and EQ within the HPG axis of male rats and endpoints measured 
in the present study 
 
            Endpoints 
Organs 
Organ weights Gene expression Serum levels 
MPOA/AH  ERα; ERβ; AR; GnRH  
MBH/ME  ERα; ERβ; AR; GnRHR  
Hippocampus  ERα; ERβ; AR  
Amygdala  ERα; ERβ; AR  
Striatum  ERα; ERβ; AR  
Pituitary  
ERα; ERβ; TERP-1/-2; AR; 
GnRHR; LHβ; α- subunit; TSHβ 
LH, TSH, PRL 
Thyroid   T4 ; T3 
Testes   T; DHT 
Prostate  ERα; ERβ; AR  
Seminal vesicles  ERα; ERβ; AR  
Epididymides  ERα; ERβ; AR  




1.7. Hypothesis, objectives, and experimental paradigm 
 
As depicted in Figure 5, the hypothesis of the present study was that oral application of the 
endocrine active substances, VZ and EQ, may alter the brain function like neuroendocrine 
activity in adult male rats which is associated with altered expression of genes relevant for 
regulation of the HPG axis function in hypothalamic and limbic brain structures and pituitary. 
Therefore, the present thesis is designed to investigate in vivo potential neuroendocrine 
effects of VZ and EQ on (a) alterations of both mRNA and protein transcript levels of several 
genes that are involved in the regulation of androgen/estrogen-dependent non-reproductive 
and reproductive processes in particular areas of brain (MBH/ME, MPOA/AH, striatum, 
amygdala, and hippocampus) and pituitary. In addition, mRNA expression in the prostate, 
seminal vesicles and epididymides as the androgen-dependent reference organs was also 
evaluated; (b) wet weights at autopsy of ventral prostate, seminal vesicles, epididymides, 
and liver; (c) serum concentrations of reproductive hormones (LH, T, DHT, PRL) and thyroid 
parameters (TSH, T4, T3); (d) serum levels of cholesterol, high- and low-density lipoproteins, 




Figure 5.  Schematic diagram of the in vivo model to investigate the possible endocrine-disrupting 
effects of VZ and EQ on the brain and its neuroendocrine function like regulation of the HPG axis in 
adult male rats. 
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In the present investigation adult male rat, an internationally accepted test system for 
detection of antiandrogenic endocrine disrupting substances with potential relevance to the 
human health as previously recommended by the OECD (Gray et al., 2004; O'Connor et al. 
2002; Shin et al., 2006), was used. Since E2, converted from T by local aromatase, affects 
the HPG axis in the male rat, this animal model is also suitable to describe estrogenic effects 
of an ED. Male rats were treated for 5 consecutive days with the test compounds orally per 
gavage to imitate the major route of human and animal exposures to these EDs, and also the 
activity of the gut microflora and the first-pass metabolism of these compounds (Chang et al., 
1995; Kelce et al., 1995; Gao et al., 2006). Thereafter animals will be sacrificed. The trunk 
blood was collected and brain and various peripheral steroid receptive organs were removed. 
Levels of mRNA and protein expression of relevant genes were determined in the brain, 
pituitary, and peripheral androgen-regulated organs by means of quantitative TaqMan Real-
time polymerase chain reaction (PCR) and immunocytochemistry. Serum levels of 
reproductive and thyroid hormones or metabolic parameters, and of the test compounds 
were analyzed by using rat specific radioimmunoassays (RIA) and high performance liquid 
chromatography (HPLC), respectively. To avoid the confounding effects of the soy-derived 
phytoestrogens, genistein and dadizein, which normally are contained in the regular rodent 
diets at concentrations that could have marked effects on the in vivo endpoints of endocrine 
action (Boettger-Tong et al., 1998; Casanova et al., 1999), we used a specialized diet without 
soy ingredients, such that the data in the present study result from neuroendocrine effects 
only of the test compounds. 
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2. MATERIALS AND METHODS 
 
2.1. Test substances 
 
Equol (EQ) was obtained from the Changzhou Dahua Imp. and Exp. (Group) Corp. Ltd. 
(Changzhou, Jiangsu, China) (Fig. 6). Vinclozolin (VZ) was purchased from Sigma-Aldrich 
Laborchemikalien GmbH (Taufkirchen, Germany) (Fig. 7) and flutamide (FLUT) was 
purchased from Sigma-Aldrich Chemie GmbH (Steinheim, Germany) (Fig. 8). The test 












Regulatory status: Pharmaceutical agent; Natural product (metabolite) 
IUPAC Name: 3,4-dihydro-3-(4-hydroxyphenyl)-2H-1-benzopyran-7-ol 
Chemical Name: (RS)4′,7-dihydroxyisoflavone 
Chemical Class: Flavonoid; Isoflavone 
CAS Number: 531-95-3 
Molecular Formula: C15H14O3 
Pharmacological action: Endocrine disruptor (ERs agonist) 
 














Regulatory status: U.S. EPA and OECD registered; General Use Pesticide (non-systemic fungicide), Toxicity Class III 
IUPAC Name: (RS)-3-(3,5-dichlorophenyl)-5-ethenyl-5-methyl-1,3-oxazolidine-2,4-dione 
Chemical Name: 3-(3,5-dichlorophenyl)-5-ethenyl-5-methyl-2,4-oxazolidinedione 
Chemical Class: Organochlorine; Cyclic imide; Carbamate 
CAS Number: 50471-44-8 
Molecular Formula: C12H9Cl2NO3 
Pharmacological action: Endocrine disruptor (AR antagonist) 
 



























U.S. EPA and OECD registered; 
Pharmaceutical agent:-non-steroidal antiandrogenic drug used for  
treatment of prostate cancer 
IUPAC Name: 2-methyl-N-[4-nitro-3-(trifluoromethyl) phenyl]-propanamide 
Chemical Name: 
2-Methyl-N-[4-nitro-3-(trifluoro-methyl) phenyl] propanamide; 
α,α,α-trifluoro-2-methyl-4׳-nitro-m-propionotoluidide; 
 trifluoromethylisobutyranilide -׳nitro-3-׳4
Chemical Class: Amide; Anilide; Nitrobenzene 
CAS Number: 13311-84-7 
Molecular Formula: C11H11F3N2O3 
Pharmacological action: Endocrine disruptor (pure AR antagonist) 
 
Figure 8.  The molecular structure of flutamide and its properties. 
 
 
2.2. Animals and husbandry 
 
All animals used in this work have been treated in accordance with the European Convention 
for the protection of vertebrate animals used for experimental and other scientific purposes 
(ETS 123). All experiments were conducted following the GLP guidelines published by the 
OECD, and approved by a permit issue by the Landesamt für Verbraucherschutz, 
Braunschweig, Germany. Male and female Sprague-Dawley rats used in this study were 
either raised in the animal facility of the Universitätsmedizin Göttingen (in vivo experiment 1) 
or obtained from Winkelmann GmbH, Borchen, Germany (in vivo experiment 2). All animals 
were acclimatized to the laboratory environment for 7-14 days prior to use. Upon the day of 
arrival, animals were fed with soy-free chow (Ssniff GmbH, Soest, Germany) and water ad 
libitum, and housed 5-6 animals per Makrolon cage type IV under the standardized 
environmental conditions (room temperature 22-24°C, relative humidity of 50-55%, 
illumination from 06:00 until 06:00 p.m.) throughout the study period.  
 
2.3. Animals and treatments 
 
2.3.1. In vivo experiment 1: Neuroendocrine effects of VZ in adult male rats 
 
At the age of 4 months, male rats were weighed and divided by randomization into two 
treatment groups (n = 10/group), i.e. a control and a VZ group, so that there were no 
statistically significant differences among the group body weight means. Animals were 
treated orally via gavage once per day for 5 consecutive days with either the vehicle olive oil 
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previous in vivo studies, at this dose VZ alters male sexual differentiation, reproductive 
function and development without any adverse toxic effects or increased mortality (Gray et 
al., 1994; O' Connor et al., 2002). VZ suspension was prepared daily 16 h before application. 
The treatments were conducted at 8.00 a.m. During the 5-day treatment interval, the body 
weight, food intake, and clinical symptoms were recorded daily. The time line of the study 






Figure 9.  Time line of the study design of the in vivo experiment 1. 
 
 
2.3.2. In vivo experiment 2: Neuroendocrine effects of EQ in adult male rats 
 
At the age of 4 months, male rats were weighed and divided by randomization into four 
groups (n = 12/group), i.e. control-, EQ low dose-, EQ high dose-, and FLUT-group, so that 
there were no statistically significant differences between the group body weight means. 
Animals were treated orally via gavage once per day for 5 consecutive days with either the 
vehicle olive oil (1 ml/rat/day) as the negative control, EQ low dose (100 mg/kg bw/day) and 
high dose (250 mg/kg bw/day), or FLUT at a dose of 100 mg/kg bw/day. The low 
concentration of EQ was chosen to determine whether putative antiandrogenic effects of EQ 
could be detected at a dose which in female ovariectomized rats induced estrogen-like 
actions in the pituitary and uterus without adverse toxic effects or increased mortility (Rachon 
et al., 2007a; 2007c). The higher dose of EQ (250 mg/kg bw/day) was selected to determine 
potential antiandrogenic effects of EQ at a pharmacological dose. An additional group of 
animals was treated with FLUT at the dose of 100 mg/kg bw/day as positive antiandrogenic 
reference control. The dose of FLUT was selected based on previous in vivo studies, 
reporting the typical antiandrogenic effects, such as increased serum levels of reproductive 
hormones, and decreased the size of androgen-dependent male accessory reproductive 
tissues without any adverse toxic effects or increased mortality in adult male rats (O' Connor 
et al., 2002; Kunimatsu et al., 2004). Also, FLUT at this dose was in range that has been 
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previously shown to inbibit androgen-induced male sexual behavior in adult male rats 
(Sodersten et al., 1975; Gray, 1977; Gladue and Clemens, 1980). In the present study, all 
test substances were applied as a suspension in olive oil in a volume of 1 ml per animal per 
day. The treatments were conducted at 8.00 a.m. During a 5-day treatment period, the body 
weight, food intake, and clinical symptoms were recorded daily. At the end of the treatment 
interval, each male rat performed a mating test, thereafter the animals were sacrificed. The 




Figure 10.  Time line of the experimental design of the in vivo experiment 2. 
 
 
2.4. Vaginal cytology 
 
Monitoring of vaginal cytology was performed with virgin female rats (2 months old) for at 
least 4 consecutive estrus cycles prior to the mating test. Vaginal smears were collected 
daily between 09:00 and 10:00 a.m. for identification of the estrus cycle phase. The mean 
duration of the estrus cycle of young adult female rat is 4 days, comprising the 4 phases; 
proestrus (P), estrus (E), diestrus 1 (D1), and diestrus 2 (D2) that are characterized via 
changes in the vaginal cytology (Fig. 11). Vaginal cells were collected with a plastic pipette 
tip filled with 200 µl of 0.9% NaCl. The vagina was flushed 2-3 times, or until the saline 
became milky. The vaginal fluid containing the suspended cells was then transferred onto a 
10 well plastic plate (BIOPLATE, Labdesign, Sweden). To determine the estrus cycle 
phase, the unstained native vaginal cell suspension was evaluated under a light microscope 
(Zeiss axioplan microscope, Zeiss, Germany) by using the 10x objective. In the vaginal 
samples three types of cell populations are present: -proestrus: round-shaped, nucleated, 
large epithelial cells (Fig. 11A); -estrus: large irregular shaped, anucleated, cornified cells 
(Fig. 11B); -diestrus (1 and 2): leukocytes (Fig. 11C and D). 
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Estradiol secretion peaks during the afternoon of proestrus, and then declines during the 
dark period of estrus. The LH surge occurs around 3-7 p.m. In the meantime, the sexual 
receptivity is increased. Therefore, in this study male rats were cohabitated with females for 




Figure 11.  Photomicrographs of the native vaginal smears collected from female rats at proestrus (A); 
estrus (B); diestrus 1 (C); and diestrus 2 (D). All photos were taken at the same magnification (25x). 







Figure 12.  Behavioral rhythms of the rat's estrus cycle (modified from Maeda et al., 2000). ‘N’ = 
nucleated epithelial cells. ‘C’ = cornified epithelial cells. ‘L’ = leukocytes. 
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2.5. Mating behavioral testing procedure 
 
Mating behavior was tested at the end of the 5-day treatment interval with sexually receptive 
females of the same age. The test was conducted at 4 p.m. on the day of proestrus. Male 
rats were placed separately in the females’s cage, and were left overnight with the female. 
Next morning, females were checked for the presence of a vaginal plug, then the vaginal 
smear was performed to examine the presence of spermatozoa in the vaginal lavage. In this 
study, the presence of a vaginal plug and/or spermatozoa in the vaginal lavages was used as 
an indicator of positive mating behavior as previously described (Cicero et al., 2002). 
Following positive mating, the occurrence of female pregnancies was also recorded  
 
2.6. Necropsy, collection of target organs, and measurement of organ weights 
 
Two hours after the last application or after completion of the mating behavioral test, 
necropsy was performed. To avoid variations due to ‘time-of-day’ effects from each treatment 
group one animal was killed in consecutive order. Animals were rapidly decapitated under 
deep CO2 anesthesia. Blood was collected from the trunk, stored immediately on ice and 
kept at 4°C for further isolation of the serum. Brains were carefully dissected and 
immediately frozen on dry ice, and were then kept at -70°C until RNA extraction. The 
pituitaries were removed from the skull, and the anterior part was immediately snapped 
frozen in liquid nitrogen and kept at -70°C for further RNA preparation, or immediately kept in 
10% neutral buffered formalin (NBF), pH 7.0 for further histological and immunocytochemical 
studies. The testes, ventral prostates, seminal vesicles plus coagulating glands including 
luminal fluid, epididymides, and livers were dissected, carefully trimmed free of fat remnant 
and weighed. After weighing, all target organs were immediately snapped frozen in liquid 
nitrogen, and then stored at -70ºC for RNA extraction.  
 
2.7. Serum hormone analysis 
 
The blood samples were spun down by centrifugation at 3,000 rpm for 20 min at room 
temperature with an Eppendorf bench top centrifuge 5413 (Eppendorf, Hamburg, Germany) 
to isolate the serum. The serum samples were stored at -20°C until analysis of the 
concentrations of hormones, metabolic parameters, and test substances. Levels of LH, TSH, 
and PRL were measured with rat specific radioimmunoassays (RIA) supplied by the National 
Hormone and Pituitary Program of the NIH as previously described (Roth et al., 2001b). 
Serum concentrations of T, DHT, total T4 and T3 were determined with commercially 
available RIA kits (Diagnostic Systems Laboratories (DSL), Inc., Sinsheim, Germany). The 
kits were used according to instructions of the manufacturer.  
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2.8. Serum metabolic parameter analysis 
 
The concentrations of the lipid metabolic parameters, cholesterol (CHOL), high- and low- 
density lipoproteins (HDL and LDL) and triglycerides (TGs), were analyzed using an 
automatic analyzer (Roche/Hitachi 902, Boehringer, Mannheim, Germany) and commercially 
available RIA kits (Roche). The kits were used according to the manufacturer’s instructions. 
 
2.9. HPLC analysis of serum levels of the test substances 
 
Serum concentrations of test substances were analyzed by HPLC-UV detection after 
extraction and hydrolysis of the samples as previously described (Christoffel et al., 2006; 
Bottner et al., 2006b). In brief, 500 µl of serum from each animal was transferred into a 24 
well plate, mixed with an equal volume of NH4 acetate buffer (pH 5.0) containing 1 mg β-
glucuronidase (Helix pomatia β-glucuronidase and sulfatase, Type H1, Sigma-Aldrich 
Laborchemikalien GmbH, Hannover, Germany), and incubated 12 h at 37°C to eliminate 
protein binding and to hydrolyze glucuronidated or sulfated metabolites of the test 
substances. Sample cleanup was accomplished by solid phase extraction. Columns of 60 mg 
bed mass/3 ml washing and elution volume (strata-X 8B-S100-UBJ, Phenomenex Ltd. 
Deutschland, Aschaffenburg, Germany) were used according to the manufacturer’s 
instructions. Eluted substances were evaporated to dryness in a centrifugal concentrator 
(SpeedVac model SVC 200H, Savant, Alberville, USA). Samples were reconstituted with 100 
µl of absolute ethanol, and filtered through a 0.45 µm PVDF membrane (Cat. No. 
SLHVR04NL, Millipore GmbH, Schwalbach, Germany) to remove remaining protein 
contaminants. 20 µl were injected into the HPLC-UV detection system (HPLC Pump K-501, 
Knauer, Berlin, Germany). The sample was analyzed on a NC 250 x 4.6 mm, Hypersil-ODS 
5.0 µm column (Bischoff, Leonberg, Germany) protected by a precolumn 7.5 x 4.6 mm, C18 
5 µm (Jasco GmbH, Gross-Umstadt, Germany). Eluent A was ddH2O containing with 0.085% 
H3PO4, whereas eluent B was acetonitrile (100%). The flow rate was 1 ml/min with a gradient 
starting with t=0 min: A 75%, B 25%; t=5 min: A 75%, B 25%; t=10 min: A 20%, B 80%; t=25 
min: B 100%; t=30 min: B 100%; t=32 min: A 75%, B 25%. The signal was detected with an 
UV/visible spectrophotometer (LC-95, Perkin-Elmer LAS (Deutschland) GmbH, Rodgau-
Jügesheim, Germany) at λ 228 nm for VZ, at λ 260 nm for EQ, and at λ 286 nm for FLUT. 
The average retention times (min) were 15.4 (VZ), 13.2 (EQ), and 14.7 (FLUT). Serum levels 
of VZ, EQ, and FLUT were calculated on the basis of a standard curve utilizing serum spikes 
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2.10. Microdissection of brain areas 
 
Deeply frozen brains were mounted on a freezing microtome (model 1206, Leica 
Microsystems Nussloch GmbH, Wetzlar, Germany) by using Tissue-Tek O.C.T. (Sakura 
Finetek Europe, Netherland), and warmed up to a temperature of -10°C. Then brains were 
sliced into serial frontal sections (600 µm thick), thaw-mounted on a conventional glass slide, 
immediately stored on dry ice, and then kept at -70°C until use.  
 
Bilateral tissue micropunches of the MPOA/AH, amygdala, striatum, and hippocampus were 
taken from frozen coronal sections with a 1-mm-diameter stainless needle according to the 
method of Palkovits (1973). The stereotaxic coordinates according to the brain atlas of de 
Groot (Pellegrino et al., 1979) were: MPOA/AH (A 7.8, L 0.75, V -1.8); striatum (A 7.8, L 2.5, 
V 1.5); amygdala (A 7.8, L 4.5, V -2.0); hippocampus (A 4.2, L 2.0, V 2.3). The coordinates 
refer to the rostral plane of the respective section and the center of the needle (see Fig. 13 
and 14). With a sharpened scalpel, the MBH/ME was dissected between optic chiasm, 
hypothalamic grooves and mammillary bodies with a cut depth of 2 mm as described 




Figure 13.  Microdissection of the MPOA/AH, striatum, and amygdala. 
 




Figure 14.  Microdissection of the hippocampus. 
 
Figure 15.  Micodissection of the MBH/ME. 
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2.11. Tissue homogenization and RNA extraction  
 
The microdissected MBH/ME and pituitary tissues were minced with sharpened hypodermic 
needle in 500 µl of lysis buffer provided with the RNeasy Mini Kit (Qiagen, Hilden, Germany). 
Samples were further homogenized by ultrasonication for 10 sec on ice (Sonifier Cell 
disruptor model B-12, Branson Sonic Power Company, Danburg, CT, USA). Tissue 
micropunches of MPOA/AH, striatum, amygdala and hippocampus were directly disrupted 
and homogenized by ultrasonication for 10 sec on ice with an ultrasonic-cell disruptor in 250 
µl of lysis buffer as previously described (Roth et al., 2001b). Prostate, seminal vesicles, and 
epididymis tissue samples were chilled in liquid nitrogen and pulverized with a Micro-
Dismembrator (B. Braun Biotech International GmbH, Melsungen, Germany) by rapid 
agitation at 2,500 rpm for 20 sec. Approximately 30 mg fine powder of the prostate, seminal 
vesicles, and epididymis tissues were sonicated for 10 sec in 500 µl of lysis buffer.  
 
Total RNA extraction was carried out with the RNeasy Mini Kit (Qiagen) according to the 
manufacturer’s instructions. To avoid the presence of genomic DNA all samples were treated 
with DNase using the RNase-Free DNase I Set (Qiagen) after RNA extraction. Total RNA 
concentrations of the MBH/ME, pituitary, prostate, seminal vesicles, and epididymis tissue 
samples were determined by absorption measurement at 260 nm and 280 nm utilizing an UV 
spectrophotometer (Eppendorf BioPhotometer, Hamburg, Germany), then adjusted to a final 
concentration of 20 ng/µl with the RNase-free water, and immediately kept at -70°C for 
further gene expression analysis. Because of the low amount of RNA contained in the tissue 
micropunches of MPOA/AH, amygdala, striatum and hippocampus, the measurement of total 
RNA concentrations from these microdissected brain areas was performed with the 
VersaFluor fluorometer (Bio-Rad, USA) and the RiboGreen RNA Quantitation kit 
(Molecular Probes Eugene, Oregon, USA) according to the manufacturer’s instructions. The 
RNA obtained from these brain area samples was adjusted to a final concentration of 5 ng/µl 
with RNase-free water, and stored at -70°C until use for gene expression analysis. 
 
2.12. Gene expression analysis 
 
Relative changes of gene expression were determined by the two-step quantitative real-time 
reverse transcription polymerase chain reaction assay. In the first step, mRNA from the 
tissue samples was reversely transcribed to a complementary DNA (cDNA) by the Molony 
Murine Leukemia Virus Reverse Transcriptase (M-MLV RT) enzyme, using random 
oligonucleotides as primers. In the second step, cDNA is amplified with the TaqMan Real-
time PCR assay which allows for the direct quantification of the PCR products in each PCR 
cycle.  
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2.12.1. Reverse transcription 
 
Reverse transcription was performed in a thermal cycler (T3 Thermocycler, Biometra GmbH, 
Göttingen). Each reaction was carried out in a total volume of 20 µl containing 1x M-MLV RT 
reaction buffer (50 mM Tris–HCl, 75 mM KCl, 3 mM MgCl2, 50 mM dithiothreitol) (Promega, 
Madison WI, USA), 100 ng random primer hexamers (Invitrogen, Karlsruhe, Germany), 0.5 
mM dNTP mix (Invitrogen), 200 U M-MLV RT, RNase H Minus, Point Mutant (Promega), 4 
U Recombinant RNasin Ribonuclease Inhibitor (Promega), and 50 ng total RNA of 
MPOA/AH, striatum, amygdala and hippocampus, or 200 ng total RNA of MBH/ME, pituitary, 
prostate, seminal vesicles, and epididymis tissues. Samples were incubated for 10 min at 
22°C to allow primer annealing, reverse transcription was conducted at 42°C for 50 min, and 
finally RNA–cDNA hybrids and enzyme were denatured for 10 min at 95°C. Table 2 
summarizes the reverse transcription components and conditions. 
 
Table 2  Reverse transcription components and conditions per one reaction mix for cDNA synthesis 
 
Component Stock concentration Volume (µl) 
RNA template in a sterile RNase-free water 
5 ng/µl (brain tissue) or 
20 ng/µl (pituitary and 
reproductive tissues) 
10 
Random primer hexamers in 3 mM Tris-HCl (pH 7.0), 
0.2 mM EDTA 0.1 µg/µl 1 
RNase-free water - 3 
Total volume 14 
Mix gently. Incubate the mixture at 70°C for 10 min to disrupt the secondary structures, then cool 
quickly on ice for 5 min. Add the following components as below. 
M-MLV Reverse Transcriptase Reaction Buffer (50 mM 
Tris–HCl, 75 mM KCl, 3 mM MgCl2, 50 mM dithiothreitol)  
5X 4 
dNTP mix (PCR grade) 10 mM 1 
M-MLV RT, RNase H Minus, Point Mutant 200 U/µl 1 
Recombinant RNasin®, RNase Inhibitor 40 U/µl 0.1 
Total volume 20 
Mix gently. Incubate the mixture at 22°C for the initial 10 min, then 42°C for the final 50 min. 
Inactivate the reaction by heating for 10 min at 95°C.  
The cDNA can now be used as a template for the quantitative TaqMan Real-time PCR Assay. 
 
 
2.12.2. Quantitative TaqMan Real-time PCR assay  
 
The real-time quantitative TaqMan PCR assay was performed as described previously 
(Roth et al., 2001a) by using the ABI Prism®7700 Sequence Detection System (SDS) (PE 
Applied Biosystems, Foster City, CA, USA) and the qPCR core reagent kit (Eurogentec, 
Seraing, Belgium). The gene-specific TaqMan primer pairs and probes were designed with 
the Primer Express software (PE Applied Biosystems, Weiterstadt, Germany) and purchased 
from Eurogentec (Seraing, Belgium). The oligonucleotide sequences and accession numbers 
of each analyzed gene, including of the size of PCR products are summarized in Table 3. 
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Table 3  Sequences of the gene-specific TaqMan primers and probes used in the qRT-PCR assay 




2.12.2.1. Set up conditions for the quantitative TaqMan Real-time PCR assay 
 
The preparation of the 2x ABI TaqMan™ Universal PCR Master Mix from the qPCR Core kit 
(Eurogentec) is summarized in Table 4. Add all components, and mix thoroughly by inversion 
and spin down prior to use. The PCR Master Mix can be stored at 4°C for up to 14 days. 
 
Table 4  Components of 2x ABI TaqMan™ Universal PCR Master Mix 
 
Component For 1 reaction (µl) 
For 1000 reaction 
(µl) 
10x Reaction buffer 2.5 2500 
50 mM MgCl2 1.75 1750 
5 mM dNTP mix 1 1000 
HotGoldStar Taq polymerase 0.125 125 
Uracil-N-glycocylase (UNG; 1 U/µl) 0.25 250 
Ampuwa 6.875 6875 
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Amplification reactions were carried out in a 25 µl volume containing 1x Master Mix, 50–900 
nM each of gene-specific primers, 200-225 nM gene-specific probe, and 2-5 µl cDNA 
samples. The preparation of a 25 µl reaction mix is shown in Table 5. All reagents were 
added together (except for the template) into the reaction vial, mixed thoroughly using a 
vortex, and then spun down. 20 (21 or 23) µl of reaction mix was pipetted into a MicroAmp 
Optical 96-well reaction plate (Ref/No. 72.985, SARSTEDT, Nümbrecht, Germany). 5 (4 or 2) 
µl of the cDNA template, 2 µl of the cDNA standard (positive control), and ampuwa (negative 
control) with an equal volume of the cDNA template were pipetted into each corresponding 
well of a reaction plate. The plate was covered with the Optical Caps (Ref/No. 65.986, 
SARSTEDT), and spun down for 5 min at 3,000 rpm by using the mid bench centrifuge 
(Labofuge 400, Heraeus Instruments, Osterrode, Germany), and then placed into the sample 
block of the ABI Prism®7700 Sequence Detector.  
 
Table 5  Preparation of a 25 µl PCR Reaction Mix 
 
Reagent Volume (µl) Final concentration 
2x ABI TaqMan™ Universal PCR Master Mix 12.5 1X 
Forward primer (10 µM) 0.125; 0.75; 2.25 50; 300; 900 nM 
Reverse primer (10 µM) 0.125; 0.75; 2.25 50; 300; 900 nM 
Probe (10 µM) 0.5; 0.5625 200; 225 nM 
cDNA template 2; 4; 5 - 
Ampuwa 8.4375; 6.4375; 5.5 - 




In the initial step, the samples were incubated for 2 min at 50°C for elimination of carryover 
PCR products by uracil DNA glycosylase treatment, and then for 10 min at 95°C for 
activation of the HotGoldStar PCR enzyme. Subsequently, samples were amplified for 40 
cycles. Each cycle consists of a denaturation step of 15 sec at 95°C and a combined 
annealing/extension (release of fluorescent reporter) step of 1 min at 60°C. When the PCR 
run was completed, the output data were analyzed using the SDS software and exported into 
a Microsoft Excel file for analysis. 
 
The optimized concentrations of the gene-specific TaqMan primer pairs and probes are 
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Table 6  Optimized concentrations of the corresponding TaqMan primer pairs and probe of each gene 
investigated in the present study 
 
Concentration (nM) Gene 
Forward primer Reverse primer Probe 
AR 300 300 200 
ERα 50 900 225 
ERβ 300 300 225 
GnRH 900 900 225 
GnRHR 300 300 225 
LH-β 300 300 200 
α-subunit 300 300 225 
TERP-1 300 300 225 
TERP-2 300 300 225 
TSHβ 300 300 225 
 
 
2.12.2.2. Standard curves  
 
Each PCR cycle run on an ABI Prism®7700 SDS included: (a) serial dilutions of eight 
duplicate cDNA samples of known DNA concentrations from which a standard curve was 
derived, designated as ‘STND’; (b) single run of each cDNA sample from the target tissues 
labeled as unknown (UNKN); and (c) eight duplicate samples of every reagent required for 
the TaqMan PCR reaction except the target template, designated as ‘no template controls’ 
(NTC) to detect any contamination in the primer/probe mix or formation of primer dimers. 
 
The relative quantification analysis for measurement of alterations in steady-state-levels of 
mRNA expression of a particular gene in the target tissue samples was achieved by using 
the standard curve method (Larionov et al., 2005; Holzapfel and Wickert, 2007). To generate 
cRNA, a cDNA was prepared from the total RNA of a tissue that expresses the gene of 
interest. The forward primer was extended by an upstream sequence of T7, such that the 
PCR product comprises the sequence of the target gene along with the upstream T7-
sequence serving as the starter of the T7-RNA polymerase in the in vitro transcription. RNA 
was synthesized by in vitro transcription using the T7 RNA polymerase and the T7-
MEGAshortscript high yield transcription kit (Ambion, Applera Deutschland GmbH, 
Darmstadt, Germany) according to the instructions of the manufacturer. Upon the completion 
of RNA transcription reaction, the template DNA was removed by incubation with RNase-
free-DNase I (Qiagen) at 37°C for 15 min. In vitro-transcribed RNA transcripts were 
subsequently recovered and purified by phenol-chloroform extraction according to the 
instruction manual (Ambion). The quality of RNA was evaluated by using the 260/280 nm 
absorbance ratio and the size and concentration of the RNA transcripts were determined by 
automated capillary electrophoresis with an Agilent 2100 Electrophoresis Bioanalyzer 
(Agilent Technologies Sales & Service GmbH & Co. KG, Walbronn, Germany). The stock 
RNA solution was serially diluted 1:10 eight times with DNase-RNase-free water to obtain a 
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concentration range of 8 orders of magnitude. These RNA standards were then reverse 
transcribed using the M-MLV RT and random primer hexamers and amplified by TaqMan 
PCR as already described earlier (see sections 2.12.1. and 2.12.2.). The standard curve was 
generated by plotting the logarithms of concentrations of the input cDNA against the 
corresponding cycle threshold for target amplification, i.e. the Ct-value which represents the 
PCR cycle at which the first increase in reporter fluorescence above the baseline signal can 
be detected. To determine the relative gene expression levels in a target tissue sample, the 
respective sample Ct-value was plotted on the standard curve and the resulting DNA 
amounts were calculated using the built-in ABI Prism®7700 SDS software.  
 
2.12.3. Statistical analysis 
 
For calculation relative gene expression values, the mean transcript count of the control 
group was set as 100% and the data from all treatment groups were set in correlation to the 
control values. Data were presented as means ± standard error of mean (SEM). Outliers of 
the data were excluded using the Grubbs’s test as previously described (Burke, 2001). The 
differences between mean values of the control- and all treatment-groups were analyzed by 
one-way ANOVA followed with the Dunnett’s multiple comparison post-hoc test or by the 
Student’s t-test when only two groups were compared (GraphPad Prism 4.0, GraphPad 
Software, Inc., San Diego, CA, USA). P values <0.05 were considered statistically significant. 
 
2.13. Histological and immunocytochemical analyses 
 
2.13.1. Histological procedure 
 
The pituitary glands from 6 rats of each group were excised and fixed in 10% NBF for 24 h at 
room temperature. The post-fixed pituitary glands were washed with tap water for 1 h, and 
then processed with the automated, semi-enclosed tissue processor (Leica model TP1020, 
Leica Microsyteme Vertrieb GmbH, Bensheim, Germany) in a series of increasing alcohol 
concentrations (50% to 75% to 96% to 100%) to dehydrate the tissue, and the xylene for 
clearing the dehydrant from the tissue. The operating conditions for processing the tissue by 
the automatic tissue processor were summarized in Table 7. Thereafter, the tissue was 
embedded in the paraffin by using a dispenser with integrated hot plate and separated cool 
plate (Leica model EG1140C). 3-µm-thick serial transverse sections were cut with a rotary 
microtome (Leica model RM2135). The tissue sections were thaw-mounted on 
SuperFrostPlus microscope slides (MENZEL-GLÄSER, Germany) and dried for 24 h at 
37°C. The paraffin-embedded tissue sections were stained with hematoxylin/eosin according 
to standard procedures to investigate the microscopic anatomy, or immunostained with the 
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specific antibody by using the immunocytochemical technique to examine protein expression 
of the relevant genes.  
 
Table 7  Operating conditions for processing the post-fixed tissue with the automatic tissue processor 
 
Step Solutions and Reagents Incubation time (min) 
1 50% EtOH 60 
2 75% EtOH 60 
3 75% EtOH 90 
4 96% EtOH 60 
5 96% EtOH 90 
6 100% EtOH 60 
7 100% EtOH 60 
8 100% EtOH 90 
9 Xylene 60 
10 Xylene 60 
11 Hot Paraffin (70°C) 45 
12 Hot Paraffin (70°C) 45 
 
 
2.13.2. Hematoxylin and Eosin (H&E) staining technique 
 
Hematoxylin is a basic dye with an affinity for the nucleic acids of the cell nucleus, whereas 
eosin is an acidic dye with an affinity for cytoplasmic components of the cell. Utilizing H&E 
staining, in the first step the nuclei were stained blue or dark blue-violet to black by 
hematoxylin (Mayer’s hematoxylin solution, Merck KGaA, Darmstadt, Germany). In the 
second step of counterstaining with eosin, the cytoplasmic components were stained pink to 
red. Preparation of the eosin Y stock and working solutions used in the H&E staining is 
shown below. Step-by-step procedure of the standard H&E staining technique used in the 
present study is summarized in Table 8. After completion with this multistep procedure, the 
tissue slide was mounted with a xylene based mounting medium (DePex mounting medium, 
Dibutylphthalate, Merck, Darmstadt, Germany).  
 
 Eosin Y Stock Solution: 
 
 Eosin Y  1 g 
 ddH2O  20 ml 
 96% EtOH 80 ml 
 Mix to dissolve  
 Store at room temperature 
 
 
 Eosin Y Working Solution: 
 
 Stock solution 45 ml 
 80% EtOH 135 ml 
 Add 5 drops of glacial acetic acid  
 Mix thoroughly 
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Table 8  Step-by-step procedure of the H&E staining method 
 
Step Solutions and Reagents Incubation time (min) 
1 Xylene 5 
2 Xylene 5 
3 Xylene 5 
4 100% EtOH 2 
5 100% EtOH 2 
6 100% EtOH 2 
7 96% EtOH 2 
8 96% EtOH 2 
9 75% EtOH 2 
10 Double Distilled water 3 
11 Mayer’s Hematoxylin Solution 5 
12 Tap Water 5 
13 Double Distilled water 3 
14 Eosin Y Solution 1 
15 Double Distilled water 1 
16 75% EtOH 2 
17 96% EtOH 2 
18 96% EtOH 2 
19 100% EtOH 3 
20 100% EtOH 3 
21 Xylene 5 
22 Xylene 5 
23 Xylene 5 
 
 
2.13.3. Immunolocalization of ERα in the pituitary 
 
The C-terminal C1355 specific rabbit polyclonal antibody to the ERα was purchased from 
Upstate/Chemicon Cell Signalling Solutions (Germany). This antibody is generated against 
the synthetic peptide corresponding to the last 15 C-terminal amino acids (586-600) of rat 
ERα (TYYIPPEAEGFPNTI), and does not cross-react with ERβ.  
 
To localize ERα, 3-µm-thick serial sections of pituitaries from 6 rats from each study group 
were immunostained with the peroxidase–anti-peroxidase (PAP) staining technique by 
means of a Dako EnVision System as described previously (Shi et al., 1997; Rimoldi et al., 
2006). In brief, sections were dewaxed, rehydrated, and a microwave pretreatment for 
antigen retrieval was performed by boiling the tissue slides twice for 5 min each in 0.01 M 
Citric acid buffer, pH 6.0 setting the power at 750 watts. After cooling and washing in double-
distilled water and 1x PBS, endogenous peroxidase was blocked with 3% H2O2 in methanol 
for 30 min at room temperature (RT). Sections were rehydrated in a series of decreasing 
alcohols (100% to 96% to 75%), washed in 1x PBS, and then preincubated with 10 µl/ml 
normal goat serum (Dako Denmark A/S, Denmark), and 3% BSA (Gibco, Invitrogen) in 1x 
PBS for 30 min at RT to reduce non-specific binding of secondary antibody. After washing in 
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1x PBS, sections were incubated for 30 min at RT with the primary antibody (anti-ERα 
C1355) diluted 1:800 (v/v) in the antibody diluent (DakoCytomation, Dako Deutschland 
GmbH, Germany). The negative controls were incubated with antibody diluent only without 
the specific primary antibody. After washing in 1x PBS, sections were incubated with goat 
antirabbit and antimouse IgG- horseradish peroxidase (HRP)-conjugated secondary antibody 
(Envision/HRP, DakoCytomation) for 30 min at RT. After washing in 1x PBS, the sites of 
HRP were visualized with 3, 3′-diaminobenzidine tetrahydrochloride (DAB) chromogenic 
substrate (DakoCytomation) and the Mayer’s modified hematoxylin solution (Merck KGaA) as 
a nuclear counterstaining. Samples were then dehydrated following the step 16 to 23 (Table 
8) through an ethanol series and xylene, and mounted with DePex permanent mounting 
medium.  
 
Following solutions, buffers, and reagents were used for immunohistochemistry:-  
 
- 10 mM Citrate buffer, pH 6.0 
 
C6H5Na3O7. 2H2O 2.971 g 
ddH2O  up to1 liter 
Adjust the pH to 6.0 with 1 N HCl 
Adjust the volume of the solution to 1 liter 
Store at 4°C 
 
- 10 X PBS Buffer (stock solution) 
 
NaCl  80 g 
KCl   2 g 
Na2HPO4  11.5 g 
KH2PO4   2 g 
ddH2O  up to 1 liter 
Adjust pH to pH 6.8 with 1N HCl 
Adjust the volume of the solution to 1 liter 
Store at room temperature 
 
- Blocking endogenous peroxidase solution 
 
CH3OH  90 ml  
H2O2 (30%, v/v) 10 ml 
Mix well 
Store at 4°C 
 
- Blocking non-specific binding of immunoglobulins solution 
 
Bovine albumin (7.5%, v/v) 400 µl 
Goat normal serum  30 µl 
1x PBS   2570 µl 
Make up immediately prior to use 
 
- Detection reagent (DAB staining Kit) 
 
DAB+ chromogen solution 20 µl 
DAB Substrate buffer 1 ml 
Make up immediately prior to use 
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2.13.4. Quantitative analysis of the positive immunostained cells and photography 
 
Sections were examined with a standard light microscope (Zeiss), and micrographs of 
immunostained areas around sinusoid vessels in the anterior lobes of the pituitary were taken 
with a Zeiss CCD digital camera connected to a computer running a program of Soft Imaging 
System analySIS software (Soft Imaging System GmbH, Münster, Germany). 
 
Examination of positive immunostained cells was done by blinded preparation. An ocular 
micrometer with 100 squares in 0.25 × 0.25 mm was used for cell counting. Cells were 
considered positive if only the nuclear staining (brown color) was present. The number of 
positive immunostained cells regardless of intensity in five randomly selected areas of each 
tissue section from 6 rats per study group was counted separately at the magnification of 
400x, and determined as the relative percentage to the total cell numbers as described 
previously (Rimoldi et al., 2006). Significant differences between the control- and all 



























3. Results  
 
3.1. In vivo Experiment 1: Neuroendocrine effects of VZ in adult male rats 
 
3.1.1. Clinical signs, body weight gain, and food consumption 
 
Throughout the 5-day treatment interval, each animal was examined daily for clinical 
symptoms of toxicity related to VZ application. No such changes were observed. As shown in 
Fig. 16, neither mean final body weight nor average daily food intake of the VZ-treated 
animals were significantly affected compared to the vehicle treated-controls. No mortality 





















Figure 16.  Mean final body weights and average daily food intake of adult (4 months old) male rats 
treated with VZ for 5 days. Data represent means ± SEM (n = 10/group). 
 
 
3.1.2. Daily intake and serum concentration of VZ 
 
The intended dose of VZ was 150 mg/kg bw/day (or 57 mg/rat/day). The achieved dose of 
VZ based on the measured final body weight was 148.25 mg/kg bw/day (or 55.89 
mg/rat/day). The results of the HPLC analysis of the serum samples is shown in Fig. 17. The 
mean concentration of total VZ after extraction and hydrolysis was 15.64 ± 0.99 µg/ml or 
54.65 ± 3.46 µmol/l. There was no corresponding signal detectable in the chromatograms of 
serum samples of the vehicle-treated controls. 
 
3.1.3. Relative weights of reproductive and accessory sex organs  
 
Relative organ weights were calculated by dividing the final absolute organ weight by the 
final body weight of each individual animal to avoid covaration between the body and organ 




















not change upon VZ treatment. However, in the VZ-treated rats the relative epididymides 





















Figure 17.  Mean serum levels of total VZ after extraction and hydrolysis in rats after a 5-day oral 























Figure 18.  Relative weights of liver, testes, ventral prostate (VP), seminal vesicles (SV), and 
epididymides (EP) (means ± SEM, n = 10/group). *P < 0.05 versus control. 
 
 
3.1.4. Serum levels of reproductive and thyroid hormones 
 
Treatment with VZ led to a significant elevation of serum levels of LH and T. Mean serum 
TSH and total T4 concentrations were significantly decreased by VZ treatment, whereas total 





























































Figure 19.  Mean serum levels of LH, T, TSH, total T4 and T3. Data represent means ± SEM, n = 
10/group. *P < 0.05 versus control. 
 
 
3.1.5. Serum levels of metabolic parameters  
 
Serum levels of the lipid parameters cholesterol, triglycerides, high- and low-density 
lipoproteins, and serum glucose levels of VZ-treated rats did not differ from the vehicle-





















Figure 20.  Mean serum levels of cholesterol (CHOL), triglycerides (TGs), high- and low-density 
lipoproteins (HDL and LDL), and glucose (mean ± SEM, n = 10/group). *P < 0.05 versus control. 
 
 
3.1.6. mRNA expression analysis in the pituitary 
 
Relative mRNA expression levels of ERα, ERβ, and AR in the pituitary were not affected by 
VZ treatment. In contrast, relative levels of TERP-1 and -2 mRNA expression were 


































of mRNA expression levels of the GnRH receptor (GnRHR), LHβ and α-subunit, while TSHβ 




















Figure 21.  Relative mRNA expression levels of ERα, ERβ, AR, TERP-1 and -2 in the pituitary (means 























Figure 22.  Relative mRNA expression levels of GnRHR, LHβ, α-subunit, and TSHβ in the pituitary. 
Values represent means ± SEM (n = 10/group). *P < 0.05 versus control. 
 
 
3.1.7. mRNA expression analysis in the MBH/ME 
 
In the MBH/ME, relative mRNA expression of ERα, AR, and GnRH receptor were not 



























































































Figure 23.  Relative mRNA expression levels of ERα, ERβ, AR, and GnRHR in the MBH/ME (means ± 
SEM, n = 10/group). *P < 0.05 versus control.  
 
 
3.1.8. mRNA expression analysis in the MPOA/AH 
 
Expression analysis of ERα, ERβ, AR, and GnRH in the MPOA/AH revealed no significant 
effects of VZ treatment. However, tendencies towards decreased ERα and GnRH, and 





















Figure 24.  Relative mRNA expression levels of ERα, ERβ, AR, and GnRH in the MPOA/AH (means ± 
SEM, n = 10/group).  
 
 
3.1.9. mRNA expression analysis in the striatum 
 
In the striatum, expression of both ERα and ERβ remained unchanged, while a significant 
reduction of AR mRNA levels were observed. A tendency for decreased levels of ERβ mRNA 














































































Figure 25.  Relative mRNA expression levels of ERα, ERβ, and AR in the striatum (means ± SEM, n = 
10/group). *P < 0.05 versus control.  
 
 
3.1.10. mRNA expression analysis in the hippocampus 
 
Relative mRNA expresssion levels of ERα, ERβ, and AR in the hippocampus were not 
significantly affected by VZ treatment. There were tendencies for decreased ERβ mRNA 




















Figure 26.  Relative mRNA expression levels of ERα, ERβ, and AR in the hippocampus (means ± 
SEM, n = 10/group).  
 
 
3.1.11. mRNA expression analysis in the ventral prostate  
 
In the ventral prostate, VZ significantly increased and decreased levels of AR and ERβ 



















































































Figure 27.  Relative mRNA expression levels of ERα, ERβ, and AR in the ventral prostate (means ± 
SEM, n = 10/group). *P < 0.05 versus control.  
 
 
3.1.12. mRNA expression analysis in the seminal vesicles 
 
In the seminal vesicles, levels of ERα and AR mRNA expression were significantly up-




















Figure 28.  Relative mRNA expression levels of ERα, ERβ, and AR in the seminal vesicles (means ± 
SEM, n = 10/group). *P < 0.05 versus control.  
 
 
3.1.13. mRNA expression analysis in the epididymis 
 
In the epididymis, the levels of relative ERβ and AR mRNA expression were up-regulated, 




















































































Figure 29.  Relative mRNA expression levels of ERα, ERβ, and AR in the epididymis (means ± SEM, 
n = 10/group). *P < 0.05 versus control.  
 
 
A compilation of effects of a 5-day oral treatment of adult (4 months old) male rats with VZ in 
comparison with vehicle control is summarized in Table 9.  
 
Table 9  A compilation of effects of VZ on the brain and the intact HPG axis after a 5-day oral 
treatment in adult male rats 
 
Endpoints VZ-treated males 
Body weight, food consumption Terminal body weights ; Daily food intake  
Organ weights Testes ; Epididymides ; Prostate ; Seminal vesicles ; Liver  
Serum hormone levels LH ; T ; TSH ;T4 ; T3  
Serum metabolic parameter levels CHOL ; TGs ; HDL ; LDL , Glucose  
Pituitary, gene expression 
ERα ; ERβ ; AR ; TERP-1 ; TERP-2 ; GnRHR ; LHβ ; 
α-subunit ; TSHβ  
MBH/ME, gene expression ERα ; ERβ ; AR ; GnRHR  
MPOA/AH, gene expression ERα ; ERβ ; AR ; GnRH  
Striatum, gene expression ERα ; ERβ ; AR  
Hippocampus, gene expression ERα ; ERβ ; AR  
Prostate, gene expression ERα ; ERβ ; AR  
Seminal vesicles, gene expression ERα ; ERβ ; AR  
Epididymis, gene expression ERα ; ERβ ; AR  
       Note: / = significant increase/decrease compared with the controls. 






































3.2. In vivo experiment 2: Neuroendocrine effects of EQ in adult male rats 
 
3.2.1. Clinical signs, body weight gain, and food consumption 
 
Throughout the 5-day treatment interval, each individual animal was examined daily for the 
presence of any clinical signs of toxicity related to the EQ and FLUT treatments. Final mean 
body weights of animals in the EQ low and high dose and FLUT treatment group were 
slightly but significantly decreased, achieving the mean values of 96%, 95% and 97% of the 
vehicle-treated controls, respectively (Fig. 30A). All treatments reduced the daily food intake 
(Fig. 30B). No mortality was observed in all treatment- and control-groups and there was no 





Figure 30.  Effects of the 5-day oral administration with either EQ at low and high doses, or FLUT on 
(A) mean final body weights, and (B) average daily food intakes of adult (4 months old) male rats. 
Each bar represents the mean ± SEM (n = 12/group). *P < 0.05 versus control. 
 
 
3.2.2. Daily intake and serum concentrations of the test substances 
 
The intended dosages of EQ were 100 and 250 mg/kg bw/day. The intended dose of FLUT 
was 100 mg/kg bw/day. Based on the measured final body weights, EQ low dose-treated rats 
received an average dose of 99.98 mg/kg bw/day (or 37.99 mg/rat/day), while EQ high dose-
treated rats received 250.49 mg/kg bw/day (or 95.19 mg/rat/day). The achieved dose of 
FLUT was 98.96 mg/kg bw/day (or 37.60 mg/rat/day).  
 
Utilizing HPLC analysis after extraction and hydrolysis of serum samples, the determined 
mean concentrations of EQ in rats treated at low and high doses were 2.72 ± 0.44 µg/ml 
(11.24 ± 1.81 µmol/l) and 6.55 ± 0.74 µg/ml (27.02 ± 3.06 µmol/l), respectively. In rats treated 
with FLUT the serum levels were 41.00 ± 2.31 µg/ml (148.4 ± 8.36 µmol/l) (Fig. 31). No 
corresponding signals of EQ and FLUT were detectable in the chromatograms of serum 






































































3.2.3. Effects of the test substances on expression of male mating behavior 
 
In the present study, male sexual behavior was determined by successful mating with 
sexually receptive females as indicated by the presence of a vaginal plug, or spermatozoa in 
the vaginal lavages after overnight mating.The effects of the 5-day oral administration of 
adult male rats with either EQ or FLUT on mating behavior are summarized in Table 10. All 
of the vehicle-treated controls showed successful mating behavior (100%) (Fig. 32), whereas 
all of the FLUT-exposed rats failed to mate with sexually receptive females (0%) (Fig. 33). 
Comparable to the results of the vehicle-treated controls, all male rats treated with EQ either 
at low- or high-dose showed successful mating behavior (100%) (Fig. 34 and 35). Sub-acute 
treatment of male rats with EQ both at low and high doses did not affect the pregnancy 
outcome of their respective female partners. None of the female rats mated with the FLUT-
treated males became pregnant (Table 10). 
 
Table 10  Effects of a 5-day oral administration of adult (4 months old) male rats with either EQ low 











Cohabitations 10 10 11 10 
Positive vaginal lavages 10 10 11 0 
Successful mating (%) 100 100 100 0 






















Figure 32.  Two representative photomicrographs (25x) showing the presence of spermatozoa in 
vaginal lavages of sexually receptive female rats after mating with the vehicle-treated males (n = 10) 






Figure 33.  Two representative photomicrographs (25x) showing the absence of spermatozoa in 
vaginal lavages of sexually receptive females after mating with the FLUT-exposed male rats (n = 10) 






Figure 34.  Two representative photomicrographs (25x) of positive vaginal lavages of sexually 
receptive female rats after mating with the EQ low dose-treated males (n = 10) at day 5 of treatment. 
Scale bar = 50 µm. 
CTL Male No. 9 CTL Male No. 6 
FLUT Male No. 10 FLUT Male No. 6 
EQ Low Male No. 8 
 
EQ Low Male No. 7 
Estrus, Sperm Estrus, Sperm  
Estrus, No sperm Estrus, No sperm 





Figure 35.  Two representaive photomicrographs (25x) of positive vaginal lavages of sexually 
receptive females after mating with the EQ high dose-treated male rats (n = 11) at day 5 of treatment. 
Scale bar = 50 µm. 
 
 
It has been reported that EQ at a dose of 0.25 mg/kg bw/day reduced prostate size in adult 
male rats after a 4-day treatment (Lund et al., 2004). This prompted us to examine whether 
EQ at this extremely low dose affects male sexual behavior. According to the protocol of 
Lund et al. (2004), adult (4 months old) male rats were s.c. injected for 4 days with either EQ 
(0.25 mg/kg bw/day), or DMSO (0.5 ml/rat/day, vehicle control). At day 4 of treatment, all rats 
performed the mating test with sexually receptive female rats of the same age. 100% of male 
rats treated with EQ at this dose showed successful mating behavior (Fig. 36). Similarly, 




Figure 36.  Two representative photomicrographs (25x) showing the presence of spermatozoa in 
vaginal lavages of sexually receptive female rats after mating with the males s.c. injected with EQ at a 
dose of 0.25 mg/kg bw/day (n = 10) at day 4 of treatment. Scale bar = 50 µm. 
 
 
An additionally mating test was conducted to examine the reversibility of the inhibitory effects 
of FLUT on male sexual behavior. After 5 days of cessation with FLUT treatment, all rats 
were mated with sexually receptive females of the same age. 60% of FLUT-treated rats 
showed successful mating behavior (Table 11).  
EQ High Male No. 2 EQ High Male No. 8 
EQ 0.25 Male No. 5 EQ 0.25 Male No. 9 
Estrus, SpermEstrus, Sperm  
Estrus, Sperm Estrus, Sperm 
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Table 11  Mating behavior of adult male rats in response to 5 days after cessation with FLUT 






Positive vaginal lavages 6 
Successful mating (%) 60 
Pregnancies with positive matings 3 
 
 
3.2.4. Relative weights of reproductive and accessory sex organs  
 
Since the mean final body weights were different between the animal groups, relative organ 
weights are reported. Figure 37 shows the relative weights of testes, epididymides, ventral 
prostate, seminal vesicles, and liver of adult male rats after oral application of either EQ at 
low and high doses, or FLUT for 5 consecutive days. EQ both at low and high doses, and 
FLUT significantly increased the relative liver weight. EQ at high dose as well as FLUT 
markedly decreased relative weight of seminal vesicles. EQ did not exert any effects on the 
relative weights of ventral prostate and epididymides, while FLUT significantly decreased the 
relative weights of these organs. Both the EQ and FLUT treatments did not significantly 
affect the relative testicular weight. 
 
3.2.5. Serum levels of reproductive and thyroid hormones  
 
EQ at two dose applied reduced serum concentrations of LH, T and DHT, and increased 
serum PRL levels in a dose-dependent manner. In contrast, FLUT profoundly increased 
serum LH, T, and DHT levels without altering PRL concentration (Fig. 38).  
 
Mean serum TSH concentrations remained unaffected in all treatment groups. However, T4 
and T3 levels were significantly reduced by EQ at both doses and FLUT (Fig. 39). 
 
3.2.6. Serum concentrations of metabolic parameters 
 
EQ caused dose-dependent reductions in mean concentrations of serum cholesterol, high- 
and low-density lipoproteins. In addition, EQ at high dose slightly but significantly reduced 
serum triglycerides levels. In contrast, FLUT caused statistically significant increases in 
mean serum concentrations of cholesterol, high- and low-density lipoproteins, without 





































Figure 37.  Relative weights of testes, epididymides, ventral prostate, seminal vesicles, and liver 



























Figure 38.  Mean serum concentrations of LH, PRL, T, and DHT. Data represent means ± SEM (n = 











































































































































































































Figure 39.  Mean serum levels of TSH, total T4 and T3. Each bar represents the mean ± SEM (n = 





















Figure 40.  Mean serum levels of cholesterol (CHOL), triglycerides (TGs), high- and low-density 
lipoproteins (HDL and LDL) (means ± SEM, n = 12/group). *P < 0.05 versus control. 
 
 
3.2.7. mRNA expression analysis in the pituitary 
 
Expression of the ERα-splice variants, TERP-1 and -2, in the pituitary was profoundly up-
regulated by EQ in a dose-dependent manner, whereas FLUT did not affect the levels of 
mRNA transcripts of those genes (Fig. 41A). At high dose EQ caused a significant up-
regulation of ERα mRNA expression, while FLUT did not change the relative ERα mRNA 



















































































treatment group (Fig. 41A). EQ at high dose significantly down-regulated, whereas FLUT 
dramatically up-regulated the levels of GnRH receptor mRNA transcripts (Fig. 41B). EQ both 
at low and high doses did not significantly alter LHβ mRNA expression levels, whereas FLUT 
doubled the increased levels of LHβ mRNA (Fig. 41B). EQ at low dose significantly down-
regulated gonadotropin α-subunit mRNA expression, while EQ at high dose caused a 
tendency towards decreased the relative α-subunit mRNA levels. In contrast, FLUT 
increased the levels of α-subunit mRNA transcripts significantly (Fig. 41B). EQ as well as 













































Figure 41.  Relative mRNA expression levels of ERα, ERβ, AR, TERP-1 and -2 (A) and GnRHR, LHβ, 















































































3.2.8. mRNA expression analysis in the MBH/ME 
 
In the MBH/ME, neither EQ nor FLUT caused any statistically significant alterations in the 
relative ERα and AR mRNA expression levels. Only EQ at high dose decreased significantly 
the levels of ERβ mRNA transcripts. EQ low dose as well as FLUT up-regulated the levels of 




















Figure 42.  Relative mRNA expression levels of ERα, ERβ, AR, and GnRHR in the MBH/ME (means ± 
SEM, n = 12/group). *P < 0.05 versus control. 
 
 
3.2.9. mRNA expression analysis in the MPOA/AH 
 
In the MPOA/AH, mRNA expression levels of ERα, ERβ, and AR remained unaffected by 
either EQ or FLUT treatment. Only FLUT caused a significant down-regulation of GnRH 




















Figure 43.  Relative mRNA expression levels of ERα, ERβ, AR, and GnRH in the MPOA/AH (means ± 


































































3.2.10. mRNA expression analysis in the amygdala and hippocampus 
 
In the amygdala and hippocampus the mRNA expression of ERα and AR were measured. 
Neither treatment induced changes of expression of both nuclear receptors in these brain 







































Figure 44.  Relative mRNA expression levels of ERα and AR in the amygdala (A) and hippocampus 
(B) (means ± SEM, n = 12/group). 
 
 
3.2.11. mRNA expression analysis in the ventral prostate 
 
Figure 45 summarizes the effects of EQ and FLUT in the reference androgen-dependent 
organ, ventral prostate. Levels of AR mRNA were significantly up-regulated by both the EQ 
high dose and FLUT treatments. Likewise, expression levels of ERα mRNA were also 
elevated by both the EQ high dose and FLUT treatments, but the significant increase was 



















































































Figure 45.  Relative mRNA expression levels of ERα, ERβ, and AR in the ventral prostate (means ± 
SEM, n = 12/group). 
 
 
3.2.12. ERα immunolocalization in the pituitary 
 
EQ significantly upregulated the mRNA levels of ERα and the ERα splice variant TERP in 
the pituitary. To investigate whether this elevated mRNA expression is detectable at protein 
level, an immunohistochemical analysis of the anterior pituitary was performed. Utilizing an 
ERα antibody which also recognizes TERP-1 and -2, the number of ‘’ERα’’-positive cells was 
determined. Nuclear staining for ERα was detected in a large population of anterior lobe 























Figure 46.  Representative section showing the immunolocalization of ERα in the pituitary of adult 
male rat. Nuclear staining for ERα was present in a large population of anterior lobe cells, but not in 




































The ERα immunoreactive cells were counted in 5 fields in each section from 6 rats per 
group, and then determined as the relative percentage of total cells. Representative 
micrographs of stainings from each group are shown in Fig. 47. The number of 
immunoreactive ERα cells in the anterior pituitary of male rats treated with EQ at high dose 
was significantly increased compared to the controls, whereas no significant changes were 




Figure 47.  Representative sections demonstrating the immunolocalization of ERα in the pituitary of 
adult male rats treated by gavage for 5 days with either vehicle olive oil (A;a), EQ at low (B;a) and high 
doses (C;c), or FLUT (D;d). All micrographs (100x) at the right panel were taken from the negative 
control sections, whereas those at the left panel were taken from the ERα-immunostained sections 





























Figure 48.  Relative percentages of the positive ERα immunoreactive cells in the anterior pituitary. 
*P<0.05 versus control. 
 
 
An overview of effects of the 5-day oral treatment of adult (4 months old) male rats with EQ 
in comparison with FLUT is summarized in Table 12.  
 
Table 12  An overview of effects of EQ compared to that of FLUT on the brain and its neuroendocrine 
regulation of the HPG axis and control of sexual behavior in adult male rats. 
 
 





Body weight gain and Food consumption 
Final body weight    
Daily food intake    
Relative organ weights 
Testes    
Epididymides    
Seminal vesicles     
Prostate    
Liver    
Serum hormone levels 
LH    
T     
DHT    
PRL     
TSH     
T4    
T3     
Serum metabolic parameter levels  
Cholesterol     
HDL     
LDL     






































Table 12  An overview of effects of EQ compared to that of FLUT on the brain and its neuroendocrine 
regulation of the HPG axis and control of sexual behavior in adult male rats (continued). 
 





Pituitary, gene expression 
ERα    
ERβ    
AR    
TERP-1    
TERP-2    
GnRHR    
LHβ    
α-subunit    
TSHβ    
MBH/ME, gene expression 
ERα    
ERβ    
AR    
GnRHR    
MPOA/AH, gene expression 
ERα    
ERβ    
AR    
GnRH    
Amygdala, gene expression 
ERα    
AR    
Hippocampus, gene expression 
ERα    
AR    
Prostate, gene expression 
ERα    
ERβ    
AR    
Behavioral response and female parameter 
Male mating behavior Positive Positive Failed 
Female pregnancy outcome Normal Normal Failed 
    Note: / = significant increase/decrease compared with the controls. 





















4.1. In vivo Experiment 1: Neuroendocrine effects of VZ in adult male rats 
 
This is the first study to investigate possible impacts of VZ on the brain and neuroendocrine 
activity of the HPG axis in adult male rats. As endpoint parameters mRNA expression levels 
of genes relevant for the activity of the HPG axis, i.e. sex steroid receptors and sex steroid-
regulated genes, were determined in selected areas of the brain and pituitary. To evaluate 
antiandrogenic effects of VZ, gene expression in accessory sex organs was also evaluated.  
 
4.1.1. Achieved dosage of VZ after 5 days oral application 
 
The intended dose of VZ was 150 mg/kg bw/day. Due to the slightly reduced final body 
weight, the achieved dose of VZ was 148.25 mg/kg bw/day. The HPLC analysis of serum 
samples collected about 2 h after the last application revealed a mean concentration of total 
(i.e. after extraction and hydrolysis) VZ of 15.64 ± 0.99 µg/ml or 54.65 ± 3.46 µmol/l. 
Recently, Sierra-Santoyo et al. (2004) reported serum concentrations of VZ 4 h after an oral 
application of 100 mg/kg bw to adult male rats. With the method reported in this recent study, 
the authors achieved a mean VZ concentration of 20 µM. We applied 150 mg VZ/kg bw and 
determined mean serum concentration of about 50 µM. Thus, our extraction method and the 
HPLC analysis ensure a high recovery of VZ and a reliable measurement of VZ in serum 
samples.  
 
4.1.2. Effects of VZ on the reproductive organ weights and hormone levels 
 
The wet weights of accessory reproductive organs (prostate, seminal vesicles, epididymides) 
and serum levels of reproductive hormones (LH, T) are proposed by the OECD as reliable 
measures to detect antiandrogenic actions of endocrine-disrupting chemicals (O’Connor et 
al., 2002; Shin et al., 2006). The present results show that sub-acute administration of VZ 
resulted in the significant decrease in relative epididymides weight, and elevation of serum 
LH and T levels. These results confirm and extend those recently reported by O'Connor et al. 
(2002), who demonstrated decreased epididymides weight and elevated serum LH and T in 
response to oral VZ treatment of intact adult male Sprague-Dawley rats for 15 days at the 
same dose as applied in the present study. However, our short-term 5 days in vivo oral 
treatment regimen is already sufficient to alter the weight of an androgen-dependent organ 
and serum reproductive hormone levels. Therefore, a 5-day treatment should be sufficient to 
unravel an antiandrogenic property of a test compound. It should be emphasized that we 
purposely used a short application period because we knew from our own behavioral studies 
with male rats that a 5-day oral application of the antiandrogen FLUT completely suppresses 
sexual behavior, i.e. already after 5 days brain function is clearly affected. Thus, the results 
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revealed that VZ with regard to reproductive organ weights and hormone levels acts as a 
typical AR antagonist. 
 
4.1.3. Effects of VZ on the hypothalamic GnRH pulse generator 
 
VZ increased LH levels after a 5-day oral administration which is either due to a direct 
stimulatory effect on pituitary gonadotropes or to enhanced activity of hypothalamic GnRH 
neurons. A direct effect on gonadotropes is unlikely since experiments with rat pituitary cells 
in vitro revealed no effect of VZ on LH release under both basal and GnRH stimulated 
conditions (Konstantin Svechnikov, personal communication). Thus, increased LH release 
upon VZ treatment should result from increased activity of GnRH neurons. Surprisingly, 
elevated LH release was associated with decreased rather than enhanced GnRH mRNA 
expression in the MPOA/AH, where the GnRH perikaya are predominantly located. In the 
MBH/ME where the majority of GnRH axon terminals are located, expression of the GnRH 
receptor remains unaffected. However, in the pituitary the GnRH receptor mRNA levels were 
dramatically up-regulated by VZ treatment, which may be caused by enhanced GnRH 
release into the pituitary portal vessels. Hence, it is very likely that GnRH mRNA levels in the 
MPOA/AH do not reflect the processing and secretion of the neuropeptide. It has been 
shown previously that depending upon the physiological conditions, in the rat the regulation 
of hypothalamic GnRH release may be controlled at the levels of GnRH perikaya and/or their 
axon terminals, and does not reflect always in change of the preoptic GnRH mRNA levels 
(Leonhardt et al., 1999; 2000; Kang et al., 2000).  
 
It is well known that expression of the GnRH receptor in the pituitary is controlled by the 
pulsatile exposure to GnRH. Depending on GnRH pulse frequency and amplitude, the GnRH 
receptor expression levels are increased or decreased (Kaiser et al., 1997). Expression of 
the GnRH receptor in the pituitary is up-regulated. Since LH release is not affected by VZ 
directly at the gonadotropes, it is suggested that VZ at the dose applied in the present study 
apparently increased the activity of GnRH neurons which results in up-regulation of pituitary 
GnRH receptor expression. In contrast, the GnRH receptor expression in the MBH/ME 
remains unchanged which is indicative that these receptors regulate other functions in the 
CNS than GnRH release. This hypothesis is supported by a previous study in which 
application of a GnRH agonist affected expression of the GnRH receptor in the pituitary, 
MBH/ME, and MPOA/AH in a different manner (Roth et al., 2001a). No significant changes of 
levels of AR and ERα mRNA expression were observed in the hypothalamic structures, while 
ERβ expression in the MBH/ME was reduced. Thus, the hypothalamic mechanisms involved 




4.1.4. Effects of VZ on the extrahypothalamic regions  
 
The striatum and hippocampus are the extrahypothalamic sites that mediate the sex steroidal 
effects on brain function like regulation of the HPG axis (Kalra and Kalra, 1983; Levine et al., 
1991; Sagrillo et al., 1996) due to the presence of receptors (Kerr et al., 1995; Kuppers and 
Beyer, 1999; Creutz and Kritzer, 2004). Therefore, they may be potential action sites of VZ 
either directly via binding to ERs or AR, or indirectly via altering sex steroid levels. 
Considering that within the rat brain the AR is autologously regulated, i.e. when the 
circulating androgens levels are high, the AR expression will be down-regulated (Burgess 
and Handa, 1993; Handa et al., 1996), we indeed observed a significant down-regulation of 
the AR in the striatum of VZ-treated rats, while in the hippocampus AR expression remained 
unaffected. Whether the reduction of striatal AR levels is due to a direct interaction of VZ or 
its metabolites with the receptor or whether it is caused indirectly via increased serum T 
levels remains yet unknown. It is interesting to note that no significant changes of levels of 
ERα and ERβ mRNA expression were observed in the extrahypothalamic brain areas, while 
ERβ mRNA levels in the MBH/ME was significantly down-regulated. Thus, these data are the 
first evidence that VZ may affect expression of nuclear receptors in a brain area-specific 
manner. 
 
4.1.5. Effects of VZ on the pituitary function 
 
Consistent with previous reports, we demonstrate an interference of VZ with the negative 
feedback mechanism of T on pituitary LH secretion in adult male rats as indicated by 
increased serum LH and T levels which is due to its known antiandrogenic properties 
(O’Connor et al., 2002; Kubota et al., 2003). In line with the elevated LH secretion is the up-
regulation of LHβ mRNA expression and the significant increases in pituitary GnRH receptor 
and α-subunit mRNA expression following VZ treatment, which were not examined in 
previous studies (O'Connor et al., 2002; Kubota et al., 2003). Apparently, VZ enhances 
pituitary responsiveness to hypothalamic GnRH pulses, and therefore, the biosynthesis of 
GnRH receptor and LHβ- and α-subunits are increased which, in turn, induces activation of 
testicular steroidogenesis and release.  
 
While VZ did not alter the levels of ERα, ERβ, and AR mRNA levels in the pituitary, mRNA 
expression of TERP-1 and -2, which are the pituitary-specific, estrogen-induced, truncated 
ERα isoforms, were significantly elevated. Although the physiological roles of TERP-1/-2 are 
still largely unknown, it has been demonstrated that TERP-1 suppresses estrogen-induced 
transactivation by dimerization with both ERα and ERβ (Schreihofer et al., 1999; Resnick et 
al., 2000). In turn, in both female and male rats, TERP expression is profoundly up-regulated 
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by in vivo estradiol treatment (Friend et al., 1997; Mitchner et al., 1998) which may represent 
an additional tuning mechanism for estrogen actions in the rat pituitary (Tena-Sempere et al., 
2001a). Hence, the stimulatory effect of VZ or its metabolites, M1 and M2, on TERP 
expression may be attributed to an estrogenic action in the pituitary. Such an estrogen-like 
action of VZ has been shown only in vitro previously (Scippo et al., 2004; Molina-Molina et 
al., 2006). Thus, this is the first evidence for a putative estrogenic action of VZ or its 
metabolites in vivo, and therefore at least in the pituitary of adult male rat, VZ has to be 
considered as a mixed AR antagonist/ERs agonist, not as a ‘pure’ anti-androgenic as has 
been concluded from previous in vivo investigations. 
 
4.1.6. Effects of VZ on the thyroid hormone homeostasis 
 
According to the classical negative feedback concept, low serum T4 levels should lead to 
higher TSH secretion from the pituitary. In the present study, however, despite lower 
circulating thyroid hormone concentrations, the levels of serum TSH and in tendency also 
TSHβ expression were reduced by VZ. This hormonal constellation is reminiscent of changes 
observed in central tertiary hypothyroidism or thyroid hormone metabolism known as non-
thyroidal illness (Fliers et al. 2006). Since our animals did not show any signs of illness or 
abnormalities of behavior, the simultaneously reduced serum TSH and T4 levels may result 
from a direct action of VZ on the thyrotropes, resulting in reduced thyrotropin release. 
Notably, our findings of decreased serum T4 levels along with increased relative liver weights 
of VZ-treated rats are in line with a previous study demonstrating that the lowered serum T4 
levels in response to oral VZ treatment of intact adult male Sprague-Dawley rats for 15 days 
at the same dose as applied in the present study may be secondary due to the increased 
hepatic clearance of thyroid hormones following liver enzyme induction, and this was nearly 
identical to that reported for the well-known antiandrogen FLUT (O'Connor et al., 2002). 
 
4.1.7. Effects of VZ on the reproductive and accessory sex organs 
 
The prostate, seminal vesicles and epididymides are known androgen-dependent organs. In 
the present study, they were selected as ‘’reference’’ organs for an anti-androgenic action of 
VZ. Expression of AR in the prostate, seminal vesicles, and epididymis was up-regulated by 
VZ, i.e. a 5-day treatment is sufficient to unravel an antiandrogenic property of a test 
compound. Furthermore, expression levels of ERβ in the ventral prostate were down- and in 
the epididymis up-regulated, whereas ERα gene expression was not affected by VZ 
treatment in the prostate and epididymis while in the seminal vesicles it was increased. Since 
VZ has been demonstrated to directly bind to both ERα and ERβ (Scippo et al., 2004; 
Molina-Molina et al., 2006), and the alteration of ERs expression is a surrogate marker for an 
estrogen-modulated response (Shupnik et al., 1989; Mitchner et al., 1998; Tena-Sempere et 
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al., 2000; Prange-Kiel et al., 2003), it is suggested that VZ might exert estrogen-like effects in 
these organs. To the best of our knowledge, these results are the first data demonstrating 
that VZ acts as the mixed AR antagonist/ERs agonist in the prostate, seminal vesicles, and 
epididymis of adult male rats rather than as a ‘pure’ antiandrogen as concluded from 
previous in vivo studies. The results obtained so far clearly prove that data of gene 
expression analysis are reliable endpoints to further evaluate mechanisms of VZ action that 
could contribute to its in vivo deleterious effects in development and reproductive function. 
 
4.2. In vivo Experiment 2: Neuroendocrine effects of EQ in adult male rats 
 
Based on the results of the VZ-study, which revealed yet unknown estrogenic effects of the 
formerly classified antiandrogen VZ, it was investigated whether EQ, a known estrogenic 
compound, may exert antiandrogenic actions in the HPG axis in the male rat. The measures 
employed were alterations of mRNA expression of selected androgen- and estrogen-
responsive genes in particular areas of brain, pituitary, and the resulting impact on androgen-
induced male mating behavior. In addition, mRNA expression in the prostate as an 
androgen-dependent reference organ was also evaluated. The known antiandrogen FLUT 
was employed as the reference compound.  
 
4.2.1. Effects of EQ on mating behavior in the male rat 
 
Sub-acute oral administration of EQ both at low and high doses to adult male rats did not 
affect mating behavior. In a pilot study, we also examined the effects of EQ at the dose of 
0.25 mg/kg bw/day on mating behavior to confirm its antiandrogenic effects reported by Lund 
et al. (2004) who observed the reduced prostate size in intact adult male rats treated for 4 
days with EQ at this dose. This experiment was conducted with a subset of adult male rats 
s.c. injected for 4 days with either EQ or vehicle DMSO as previously described (Lund et al., 
2004). After 4 days treatment, all of these male rats performed the mating test with the 
sexually receptive females. All of them showed successful mating behavior. Thus, the 
previously reported antiandrogenic effects of EQ at a putative low dose of 0.25 mg/kg bw/day 
do not reflect in mating behavior. We therefore decide to repeat the experiment with two 
higher doses of EQ. However, even at dose of 100 or 250 mg/kg bw/day, EQ did not affect 
mating behavior. In contrast, sub-acute administration of FLUT at the dose used in this 
present study resulted in complete impairment of mating behavior in adult male rats which is 
in line with previous reports (Sodersten et al., 1975; Gray, 1977; Gladue and Clemens, 1980; 
McGinnis and Mirth, 1986). To the best of our knowledge, there are no current data available 
regarding to the effects of EQ on male mating behavior. Thus, the present data demonstrate 
that EQ did not exert antiandrogenic effects on mating behavior in adult male rats. In 
addition, the results of FLUT treatment demonstrate that a 5-day in vivo oral administration 
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utilizing intact adult male rats should be a powerful tool to characterize putative 
antiandrogenic compounds regarding male sexual behavioral effects. 
 
It may be argued that the applied dose of EQ was too low to affect mating behavior. 
However, serum concentrations of EQ measured in rats treated with 100 mg EQ/kg bw/day 
were in the range found in Asian men consuming a traditional soy-rich diet (Morton et al., 
2002; Hedlund et al., 2003). Serum concentrations of rats treated with 250 mg EQ /kg 
bw/day were at a pharmacological level (≈ 3 x 10-5 M). At this concentration EQ profoundly 
inhibits proliferation of steroid receptive breast and prostate cancer cells (unpublished own 
data). Therefore, the EQ concentration achieved in the serum is clearly sufficient to induce 
biological effects. Thus, it may be possible that even at this high level EQ does not cross the 
blood brain barrier (BBB). This interpretation is substantiated by the finding that we observed 
only in the MBH/ME an effect of EQ on gene expression. The collected tissue sample 
contains the eminentia mediana which is outside the BBB which is accessible for EQ while 
those brain areas which control behavior, however, are not. Thus, it is unlikely that in human 
males EQ at concentrations measured in serum of men consuming soy affect brain function 
directly. 
 
4.2.2. Effects of EQ on the reproductive organ weights and hormone levels 
 
Of the OECD classical endpoints examined in the present study, FLUT revealed the 
anticipated typical pattern of antagonistic effects both at the peripheral and central AR 
functions, i.e. decreased weights of ventral prostate, seminal vesicles, and epididymides, and 
increased levels of serum LH, T, and DHT without any alteration in serum PRL levels as 
previously described in the intact adult male rat assay (O’Connor et al., 1998a; 2002; 
Andrews et al., 2001; Kunitmatsu et al., 2004). The effects of EQ on alterations in serum 
concentrations of reproductive hormones were completely opposite to those exerted by 
FLUT. EQ at high dose partially induced an antiandrogenic effect by reducing the relative 
weight of seminal vesicles with no changes of relative weights of ventral prostate and 
epididymides. Thus, on a molar base EQ is a weak antiandrogen compared to FLUT which 
becomes apparent only in the very androgen-sensitive seminal vesicles. It is therefore 
concluded that EQ and FLUT interfere with the activity of HPG axis by different mechanisms 
of action, and EQ did not completely exert antiandrogenic effects on the reproductive organ 
weights and serum reproductive hormone levels. As demonstrated for FLUT, our results, in 
addition, indicated that the 5-day intact adult male rat assay should be a powerful tool to 
characterize putative antiandrogenic EDs regarding neuroendocrine regulation of the HPG 





4.2.3. Effects of EQ on the hypothalamic GnRH pulse generator 
 
In the MPOA/AH where most of the GnRH perikaya are located, EQ at high dose decreased 
levels of GnRH mRNA transcripts, however, this effect did not reach significance. Since we 
suggest that EQ does not cross the BBB, the effect of EQ on GnRH expression must be 
indirect, possibly via the significantly reduced T-levels. In the MBH/ME where most of the 
GnRH axons are terminated, EQ low dose significantly increased levels of GnRH receptor 
mRNA expression, while in the pituitary EQ reduced GnRH receptor mRNA levels. It is well 
known that in the rat the regulation of the GnRH receptor depends on pulsatile exposure to 
GnRH (Norwitz et al., 1999; Roth et al., 2001a). EQ reduced LH secretion which is either due 
to a direct effect at the gonadotropes or indirect via reduced activity of GnRH neurons. The 
latter explanation would be in line with the reduced expression of the GnRH receptor in the 
pituitary. Thus, it is very likely that GnRH mRNA levels in the MPOA/AH do not always reflect 
the processing and secretion of the neuropeptide as reported previously (Leonhardt et al., 
1999; Kang et al., 2000). In contrast, FLUT treatment resulted in decreased levels of GnRH 
mRNA expression in the MPOA/AH, and dramatically up-regulated GnRH receptor mRNA 
levels in the MBH/ME and pituitary. These results suggested that in adult male rats FLUT 
increases hypothalamic GnRH- and pituitary LH-release due to the relief of the AR-mediated 
negative feedback effects of endogenous androgens on the hypothalamus and pituitary. 
However, it was curious that FLUT did not alter the levels of AR mRNA expression in the 
MPOA/AH and MBH/ME. Our findings were nevertheless similar to those of McAbee and 
Doncarlos (1999), who found that treatment of intact male rats with FLUT at doses that 
significantly decreased accessory sex organ weights did not alter AR mRNA expression in 
either the MPOA or ventromedial hypothalamus, and suggested that AR mRNA expression in 
these brain regions at adulthood are not affected by FLUT. Taken together, our results 
revealed that the hypothalamic effects of EQ and FLUT comprised changes of GnRH and 
GnRH receptor expression. 
 
4.2.4. Effects of EQ on the extrahypothalamic structures 
 
In the extrahypothalamic brain regions (i.e., amygdala, hippocampus) that mediate the 
androgen and estrogen effects on the regulation of the HPG axis and male sexual behavior 
(Kostarczyk, 1986; Burgess and Handa, 1993; Kerr et al., 1995; McGinnis et al., 1996), both 
EQ and FLUT did not significantly alter mRNA expression levels of AR and ERα. However, 
the present finding that the hippocampal AR mRNA levels did not significantly increase by 
FLUT treatment is surprising. Since previous studies have demonstrated that the expression 
of AR mRNA in hippocampus of adult male rats was generally up-regulated following short-
term castration, and this effect was reversed by treatment with androgens (Quarmby et al., 
1990; Burgess and Handa, 1993; Handa et al., 1996). A possible explanation may be that the 
DISCUSSION 
61 
decrease in the androgenic stimulus following FLUT treatment was not sufficient and would 
be more evident in the castrated rat model (Turner et al., 2001). Our finding of unchanged 
AR mRNA expression levels in the amygdala upon both treatments is consistent to those 
previously reported by Burgess and Handa (1993) in which in the amygdala of adult male 
rats the AR mRNA levels were not influenced by either castration, DHT, or estradiol 
administration. Taken together, our results revealed that the extrahypothalamic mechanisms 
of EQ and FLUT actions share changes of ERα and AR expression. In addition, these results 
demonstrated that the regulation of ERα and AR in the hippocampus and amygdala upon 
sub-acute EQ or FLUT exposure are not related to male mating behavior, since similar 
pattern of changes of those gene expression were found in the EQ- and FLUT-treated rats, 
while only FLUT suppressed mating behavior. 
 
4.2.5. Effects of EQ on the pituitary function 
 
EQ had notable effects on LH and PRL secretion. It is well known that estradiol is a 
stimulator of PRL secretion both in vitro and in vivo (Lieberman et al., 1981; Jordan et al., 
1984; Jarry et al., 1986), whereas androgens exert opposite effects (Giguere et al., 1982; 
Tong et al., 1989). In support of the estrogenic effects of EQ on pituitary LH and PRL 
secretion, there are several reports describing a decrease in serum LH and increase in 
serum PRL levels in response to estradiol exposure of adult male rats (O'Connor et al., 
1998b; Tena-Sempere et al., 2001a; 2001b). To our knowledge, direct effects of EQ on male 
rat pituitary cells have not been investigated yet. The present data provides therefore a first 
indication for direct estrogenic effects of EQ on both gonadotropes and lactotropes in adult 
male rats.  
 
The EQ-induced changes on LH and PRL release may be mediated via ERα and TERP 
because EQ increased levels of ERα and TERP mRNA transcripts in a dose-dependent 
manner. To support this hypothesis, the present results revealed that ERα is localized to 
most anterior pituitary cells as previously described (Mitchner et al., 1998; Shughrue et al., 
1998; Schlecht et al., 2004) and the EQ treatment significantly increased the nuclear ERα 
mRNA/protein transcripts as have been previously demonstrated with the estradiol treatment 
(Shughrue et al., 1998; Rachon et al., 2007a). Also, ERα has been previously reported to 
mediate the direct effects of estrogen in pituitary cells, since ERα knockout mice displayed 
markedly reduction in PRL mRNA levels and elevated gonadotropin mRNA levels (Scully et 
al., 1997). Furthermore, it has been demonstrated that in female and male rats the 
expression levels of the pituitary-specific, truncated isoform of rat ERα, TERP-1, is 
profoundly elevated by estradiol treatment (Friend et al., 1997; Mitchner et al., 1998; Tena-
Sempere et al., 2001a), suggesting that the TERP-1 is an important mediator of the effects of 
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estrogen in the pituitary (Friend et al., 1995). In agreement with our results, acute treatment 
with estradiol (Mitchner et al., 1998), and chronic EQ exposure (Rachon et al., 2007a) did not 
affect pituitary ERβ expression in adult ovariectomized rats, but TERP-1 mRNA expression 
levels were dramatically increased. In contrast, FLUT tended to up-regulate ERβ mRNA 
expression in the pituitary, whereas it did not affect the expression levels of ERα and TERP. 
To our surprise, pituitary AR mRNA expression was not changed by FLUT treatment, but 
nevertheless, this result is in agreement with previous data reported by Ohsako et al. (2003). 
 
EQ did not affect the levels of LHβ mRNA transcripts, but slightly reduced α-subunit 
expression. Dalkin et al. (1989; 2001) demonstrated that pulsatile GnRH release can 
selectively increase the levels of gonadotropin subunit gene expression and release in male 
rat pituitary, and that a lack of this stimulation decrease gonadotropin subunit mRNA levels. 
Hence, the decreased levels of α-subunit mRNA expression by the EQ treatment could be 
caused by the decreased GnRH stimulation of gonadotrope cells as mentioned already 
above. Consequently, the levels of serum LH were substantially decreased, which in turn 
reduced the testicular steroidogenesis, and thereby decreased serum levels of T and DHT. 
Opposite effects were observed following FLUT treatment. Consistent with previous studies 
(Ohsako et al., 2003; Kubota et al., 2003), FLUT stimulated levels of LHβ, α-subunit, and 
GnRH receptor mRNA transcripts which can be explained that FLUT could enhance GnRH 
pulses due to the disruption of negative feedback of endogenous androgens on the 
hypothalamic GnRH pulse generator. Taken together, effects of EQ and FLUT in the pituitary 
were different due to the opposite changes in ERα-, TERP-1/-2-, GnRH receptor-, LHβ-, and 
α-subunit expression. 
 
4.2.6. Effects of EQ on thyroid hormone system 
 
Both EQ and FLUT at the dose applied decreased serum T4 and T3 without any significant 
alteration in serum TSH levels, while TSHβ gene expression was significantly down-
regulated in all treatment groups. This discrepancy cannot be explained at present, however, 
our findings of decreased serum T4/T3 levels along with increased relative liver weights of 
FLUT-treated rats were consistent with previous studies demonstrating that the lowered 
serum T4/T3 levels following FLUT exposure to adult male rats was due to a secondary 
mechanism induced by the increased hepatic clearance of thyroid hormones following liver 
enzyme induction (O'Connor et al., 1998a; 2002; Andrews et al., 2001). However, it is also 
possible that EQ inhibits the thyrotropes such that they cannot compensate low T4 levels via 
increased TSH biosynthesis. Such an effect has been described recently for the endocrine 
disruptor octyl-methoxycinnamate (OMC) (Klammer et al., 2007). As demonstrated for FLUT, 
it is reasonable to postulate that EQ may also induce liver enzyme activities, giving rise to the 
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increased liver weights along with decreased serum T4/T3 levels in a similar manner to FLUT. 
To our knowledge, this is the first study demonstrating an adverse effect of EQ on thyroid 
hormone homeostasis in adult male rats.  
 
4.2.7. Effects of EQ on the metabolic parameters 
 
Recent studies from our laboratory have demonstrated that sub-acute treatment of adult 
ovariectomized rats with natural estrogen or estrogen-like compounds resulted in the 
dramatic reductions in serum concentrations of lipid parameters, i.e. cholesterol, HDL, and 
LDL (Klammer et al., 2005; Schlecht et al., 2006; Rachon et al., 2007b). According to these 
studies, EQ clearly shows estrogen-like effects in adult male rats by decreasing serum levels 
of lipid parameters. Moreover, EQ at high dose caused a significant decrease in serum 
concentration of triglycerides, and this result is in agreement with the previous study of our 
group demonstrating that chronic EQ treatment has profound effects on serum triglycerides 
levels in adult ovariectomized rats (Rachon et al., 2007b). The decreased levels of serum 
lipid parameters reflect the decreased lipid metabolism that could contribute to a significant 
reduction in the terminal body weights of EQ-treated rats as previously demonstrated 
(Rachon et al., 2007b). In contrast, treatment with FLUT caused significant increases in 
circulating cholesterol, HDL, and LDL, without changing triglycerides levels. Comparable to 
our study, it has been previously reported that the concentrations of total plasma cholesterol 
and phospholipids were highly significant increased in adult male rats treated with FLUT at 
the same dose as used in this study (Kunimatsu et al., 2004; Mannaa et al., 2005), and this 
may also contribute to the increased relative liver weight. Hence, our data demonstrated that 
EQ and FLUT exert their regulatory influences on lipid metabolism through the different 
modes of action.  
 
4.2.8. Effects of EQ on the prostate function 
 
Up-regulation of AR mRNA expression in intact adult rat ventral prostate is a robust marker 
for antiandrogenic effect of FLUT within this androgen-dependent tissue (Kumar et al., 1997; 
2002). Similarly, an up-regulation of the AR was also observed in the ventral prostate of EQ 
high dose-treated males. However, in this study, the EQ high dose treatment did not 
decrease the relative ventral prostate weight. Since EQ does not bind to AR (Lund et al., 
2004), our results may point to a different mechanism underlying the up-regulation of AR in 
the ventral prostate by EQ or FLUT. A decrease in circulating T levels causes activation of 
AR gene and up-regulation of AR mRNA levels (Kumar et al., 1997; 2002). Since the EQ 
high dose treatment resulted in very low levels of circulating T via reduction of LH secretion, 
this data suggest that the up-regulation of AR mRNA expression by EQ high dose treatment 
may be due to the estrogenic effect of EQ on LH release.  
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It is interesting to note that FLUT caused the up-regulation of ERα mRNA levels in the 
prostate, whereas EQ did not. This data was somehow unexpected as the observed results 
of FLUT exposure caused clear-cut effects on hormone responsiveness, prostate weight, 
and prostatic AR gene expression in a typical pattern of a potent AR antagonist. Also, FLUT 
has neither estrogenic nor antiestrogenic effects both in vitro and in vivo (McGinnis and 
Mirth, 1986; Laws et al., 1996; O'Connor et al., 1998a; Kim et al., 2002). Thus, the up-
regulation of ERα mRNA levels upon FLUT treatment, may therefore be causally related to 
the net temporal increase in estrogenic stimulus, perhaps as a result of elevated E2 levels 
following the aromatic conversion of elevated T to E2, that may still exist within the prostate 
due to the attenuation of the androgenic stimulus upon FLUT treatment as described 




In conclusion, the present study provided the first in vivo data demonstrating that: 
1. VZ is not a ‘pure’ antiandrogen, since it exerts mixed AR antagonistic/ERs agonistic 
actions observed at the levels of mRNA expression of selected AR- and ERs-
regulated genes in the brain, pituitary, and male accessory sex organs; 
2. EQ displays a clear-cut endocrine activity within the HPG axis which is attributed to 
be estrogenic; 
3. EQ does not exert any antiandrogenic effects on brain, pituitary and prostate 
functions, and on male mating behavior; 
4. FLUT exerts its potent antiandrogenic actions in the brain and its neuroendocrine 
regulation of the HPG axis, and control of androgen-induced male mating behavior; 
5. As demonstrated for FLUT, a short-term (5 days) in vivo oral administration utilizing 
intact adult male rats should be a powerful tool to characterize putative 







Numerous anthropogenic chemicals and natural plant-derived products can mimic or disrupt 
the normal function of endogenous sex steroid hormones by direct interaction with their 
specific nuclear receptors. These compounds were classified as ‘Endocrine Disruptors’ 
(EDs). However, there is increasing evidence that at least some EDs are rather promiscuous 
with regard to the sex steroid receptor selectivity, i.e. they bind to more than one nuclear 
receptor. An example of such promiscuous EDs is fungicide Vinclozolin (VZ) which can exert 
androgen receptor (AR) antagonistic as well as estrogen receptors (ERs) agonistic actions. 
Likewise, Equol (EQ), a metabolite of the isoflavonoid daidzein, interacts with ERs, however, 
as suggested recently, EQ may also exert antiandrogenic activity. Despite the proven 
adverse effects of EDs on development and reproductive function, however, little efforts have 
been made to investigate the potential pharmacological actions of VZ and EQ on a variety of 
brain functions, particularly the neuroendocrine regulation of the HPG (hypothalamo-pituitary-
gonadal) axis function when male individuals are exposed to these EDs. Therefore, the 
present study is designed to investigate whether and how VZ and EQ affect the brain and 
neuroendocrine function in adult male rats upon 5-days oral treatment. 
 
Examined parameters were potential effects of VZ and EQ on gene expression in the brain 
(medial preoptic area/anterior hypothalamus (MPOA/AH), mediobasal hypothalamus/median 
eminence (MBH/ME), striatum, hippocampus and amygdala), pituitary, prostate, seminal 
vesicles, and epididymis. In addition, the impact of equol on male mating behavior was 
examined. As reference compound, the pure antiandrogenic drug flutamide (FLUT) was 
employed. At the end of treatment interval or after completion with mating test, animals were 
sacrificed. The trunk blood was collected and brains and pituitaries were removed. 
Prostates, seminal vesicles, epididymides, testes, and livers were dissected and weighed. 
Changes in levels of serum hormones (LH, T, DHT, TSH, T4, T3) and mRNA expressions of 
relevant genes (sex steroid receptors, sex steroid-regulated genes) were measured by RIA 
and qRT-PCR, respectively. Serum concentrations of test substances were analyzed by 
HPLC-UV detection. 
 
The present study revealed that VZ decreased weight of epididymides and increased serum 
levels of LH and T. In the hypothalamic brain areas, VZ affected the expression of GnRH and 
both ERs subtypes ERα and ERβ. In the extrahypothalamic brain areas, VZ altered 
expression of both AR and ERs. In the pituitary, VZ up-regulated expression of GnRH 
receptor, LHβ, α-subunit, and TERP-1/-2. In the prostate, VZ increased and decreased levels 
of AR and ERβ mRNA, respectively. In the seminal vesicles, VZ increased levels of AR and 
ERα mRNA expression. In the epididymis, VZ up-regulated AR and ERβ mRNA levels. Upon 
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the pituitary-thyroid axis, VZ exerted direct effects on the pituitary thyrotropes resulting in 
decreased serum TSH and T4 levels.  
 
While FLUT displayed the typical pattern of an AR antagonist, such as decreased weights of 
ventral prostate, seminal vesicles, and epididymides, and increased levels of serum LH, T 
and DHT without effects on serum PRL levels, EQ exerted opposite effects. The 
hypothalamic effects of EQ and FLUT comprised changes of GnRH and GnRH receptor 
expression, while in the extrahypothalamic areas both compounds altered ERα and AR 
expression in a similar manner. In contrast, effects of EQ and FLUT in the pituitary were 
different due to the opposite changes in ERα-, TERP-1/-2-, GnRH receptor-, LHβ-, and α-
subunit expression. In the prostate, EQ and FLUT both affected ERα and AR expression. EQ 
did not modulate the expression of male mating behavior, whereas FLUT completely 
inhibited it. The similar reductions in serum T4 and T3 levels caused by EQ and FLUT 
treatments was primary due to the direct action on the thyrotropes, and secondary to the 
hepatic clearance of thyroid hormones following liver enzyme induction as assessed by the 
increased liver weight.  
 
In summary, the present study provided the first in vivo data demonstrating that: 
1. VZ is not a ‘pure’ antiandrogen, since it exerts mixed AR antagonistic/ERs agonistic 
actions observed at the levels of mRNA expression of selected AR- and ERs-
regulated genes in the brain, pituitary, and male accessory sex organs;  
2. EQ displays a clear-cut endocrine activity within the HPG axis which is attributed to 
be estrogenic;  
3. EQ does not exert any antiandrogenic effects on brain, pituitary and prostate 
functions, and on male mating behavior; 
4. FLUT exerts its potent antiandrogenic actions in the brain and its neuroendocrine 
regulation of the HPG axis, and control of androgen-induced male mating behavior; 
5. As demonstrated for FLUT, a short-term (5 days) in vivo oral administration utilizing 
intact adult male rats should be a powerful tool to characterize putative 








Zahlreiche anthropogene Chemikalien und Pflanzeninhaltsstoffe können die Funktion der 
endogenen Sexualsteroide durch eine direkte Interaktion mit deren spezifischen nukleären 
Rezeptoren beeinflussen. Derartige Substanzen werden als „Endokrine Disruptoren (EDs)“ 
bezeichnet. Es mehren sich aber die Hinweise, dass zumindest einige EDs hinsichtlich der 
Interaktion mit Steroidrezeptoren eine geringe Selektivität aufweisen, i.e. diese promisken 
EDs binden an mehr als einen nukleären Rezeptor.  
 
Ein Beispiel für einen derartigen promisken endokrinen ED ist das Fungizid Vinclozolin (VZ), 
welches am Androgenrezeptor (AR) antagonistische, am Östrogenrezeptor (ER) hingegen 
agonistische Wirkungen ausüben kann. Ein zweites Beispiel ist Equol (EQ), ein Metabolit des 
Isoflavonoids Daidzein. Es ist vielfach gezeigt worden, dass Equol mit dem ER interagiert, 
aber neueste Daten weisen auf eine mögliche Androgene Wirkung von EQ hin.  
 
Trotz der eindeutigen negativen Wirkungen von EDs auf die Entwicklung und Funktion 
reproduktiver Organe gibt es keine Untersuchungen zur möglichen Wirkung von VZ und EQ 
auf die Funktion des ZNS, insbesondere die neuroendokrine Regulation der hypothalomo-
hypophysio-gonadalen Achse (HPG-Achse). Daher ist die Zielsetzung der vorliegenden 
Studie die Untersuchung, ob und wie VZ und EQ die neuroendokrine Regulation der HPG-
Achse in erwachsenen, männlichen Ratten nach einer fünftägigen oralen Behandlung 
beeinflussen. 
 
Als Zielparameter wurde die Genexpression in der medialen, präoptischen Region des 
vorderen Hypothalamus (MPOA/AH), des mediobasalen Hypothalamus/Eminentia mediana 
(MBH/ME) sowie im Striatum, Hippocampus, Amygdala sowie der Hypophyse untersucht. 
Als Referenzorgane für steroidregulierte Gewebe wurden Prostata, Samenblase und 
Nebenhoden gewählt. Im Fall des Equols wurde zusätzlich der Effekt diese EDs auf das 
Sexualverhalten der männlichen Ratten untersucht. Als Goldstandard für ein reine 
Antiandrogen wurde Flutamid (FLUT) verwendet. Nach Beendigung der Behandlung, bzw, 
des Verhaltenstests, wurden die Tiere tierschutzgerecht getötet, das Blut gesammelt und die 
oben genannten Organe präpariert. Von der Prostata, der Samenblase, dem Nebenhoden 
und der Leber wurde das Frischgewicht bestimmt. In der Blutprobe wurden die 
Konzentrationen der Hormone LH, Testosteron (T), Dihydrotestosteron (DHT), TSH, T4, T3 
sowie die Konzentrationen der Testsubstanzen selbst durch Radioimmunoassay bzw. HPLC 
bestimmt. Die Genexpression von Steroidrezeptoren sowie von steroidrezeptor-regulierten 
Genen in den oben genannten Organen wurde per Taqman-PCR gemessen. 
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Die VZ-Behandlung resultierte in einem signifikant geringeren Gewicht der Nebenhoden und 
erhöhten Serumspiegeln von LH und T. Im Hypothalamus beeinflusste VZ die Expression 
von GnRH und von ERα und ERß. In den extrahypothalamischen Arealen verursachte VZ 
eine Veränderung der Expression sowohl des ARs als auch der ERs. Die hypophysäre 
Expression von LH, von TERP 1/2 sowie des GnRH-Rezeptors wurde durch VZ 
hochreguliert. In der Prostata hingegen reduzierte VZ die Expression des ERß und erhöhte 
die mRNA-Spiegel des AR. In der Samenblase bewirkte die Behandlung mit VZ eine erhöhte 
Expression des AR und des ERα. Im Nebenhoden erhöhte sich unter VZ-Behandlung die 
Expression des AR und ERß. Die reduzierten Serumwerte von TSH und T4 werden 
wahrscheinlich durch einen direkten Effekt von VZ auf die thyreoptropen Zellen der 
Hypophyse hervorgerufen.  
 
FLUT erzeugte das erwartete Muster von Effekten eines AR-Antagonisten, i.e. reduzierte 
Gewichte der Prostata, der Samenblase und des Nebenhodens und erhöhte Serumspiegel 
von LH, T und DHT ohne Effekte auf die Prolaktinspiegel. EQ hingegen induzierte 
gegensätzliche Effekte. EQ als auch FLUT veränderten im Hypothalamus die Expression von 
GnRH und des GnRH-Rezeptors während in den extrahypothlamischen Arealen beide 
Substanzen die Expression von ERα und AR in identischer Weise veränderten. In der 
Hypophyse hingegen waren unter EQ bzw. FLUT-Behandlung gegenläufige Effekte auf die 
Expression von ERαm TERP 1/2, des GnRH-Rezeptors, der LHα und ß-Untereinheit zu 
messen. Die Expression des ERα und des AR in der Prostata wurde sowohl durch EQ als 
auch durch FLUT beeinflusst.  
 
Die fünftägige Behandlung der männlichen Ratten mit drei verschiedenen Dosierungen von 
EQ führte in keiner Behandlungsgruppe zu einer Veränderung des Sexualverhaltens. FLUT 
hingegen unterdrückte das Sexualverhalten in allen getesteten Tieren komplett. 
 
Die Serum T4- und T3- Spiegel wurden durch EQ und FLUT signifikant reduziert, was auf 
eine direkte Wirkung der Testsubstanzen auf die thyreotrophen Zellen der Hypophyse 
hinweist. Möglicherweise trägt auch der erhöhte hepatische Metabolismus der 
Schilddrüsenhormone zu deren reduzierten Serumspiegeln bei. Diese Interpretation einer 









Zusammenfassend können aus der vorliegenden Studie folgende Schlussfolgerungen 
gezogen werden: 
1. In vivo ist VZ kein reines Antiandrogen, sondern besitzt sowohl AR-antagonistische 
als ER-agonistische Eigenschaften im Gehirn, der Hypophyse und akzessorischen 
Geschlechtsorganen.  
2. Equol hat eine ausgeprägte ED-Aktivität auf die HPG-Achse, die ausschließlich auf 
eine östrogene Wirkung zurückzuführen ist. Weder im Gehirn, der Hypophyse noch in 
peripheren Organen wie der Prostata konnten eine signifikante antiandrogene 
Wirkung von EQ nachgewiesen werden. 
3. Die Referenzsubstanz FLUT erwies sich als ein starkes Antiandrogen hinsichtlich der 
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9. LIST OF ABBREVIATIONS 
 
α-subunit = gonadotropin alpha-subunit 
ANOVA = analysis of variances 
AR  = androgen receptor 
ARE  = androgen response element 
BSA  = bovine serum albumin 
bw  = body weight 
°C  = degree celcius 
cDNA  = DNA complementary to RNA 
CHOL  = cholesterol 
CNS  = central nervous system 
Ct  = cycle threshold 
ddH2O  = double distilled water 
DHT  = dihydrotestosterone 
DNA  = deoxyribonucleic acid 
DNase  = deoxyribonuclease 
DMSO  = dimethylsulfoxide 
dNTP  = deoxyribonucleoside triphosphate  
EDs  = endocrine disruptors 
EDSTAC = U.S. EPA task force on the EDs 
EQ  = equol 
ERα  = estrogen receptor subtype alpha 
ERβ  = estrogen receptor subtype beta 
ERE  = estrogen response element 
ERs  = estrogen receptors 
et al.  = et alii or ‘and others’ 
EtOH  = ethyl alcohol or ethanol 
E2  = 17β-estradiol 
FAM  = 6-carboxy-fluorescein 
FLUT  = flutamide 
FSH  = follicle-stimulating hormone 
g  = gram 
GnRH  = gonadotropin-releasing hormone 
GnRHR = gonadotropin-releasing hormone receptor 
h  = hour 
HDL  = high density lipoprotein 
H&E  = hematoxylin and eosin 
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HPG  = hypothalamo-pituitary-gonadal axis 
HPLC  = high performance liquid chromatography 
HRP  = horseradish (Armoracia rusticana) peroxidase 
i.e.  = id est or ‘that is’ or ‘in other words’ 
kg  = kilogram 
λ  = lambda (wavelength) 
l  = liter 
LDL  = low density lipoprotein 
LH  = luteinizing hormone 
LHβ  = beta subunit of luteinizing hormone 
M  = molar 
MBH/ME = mediobasal hypothalamus/median eminence 
µg  = microgram 
µl  = microliter 
µM  = micromolar 
mg  = milligram 
min  = minute 
ml  = milliliter 
mM  = millimolar 
M-MLV RT = Moloney Murine Leukemia Virus Reverse Transcriptase 
MPOA/AH = medial preoptic area/anterior hypothalamus 
mRNA  = messenger ribonucleic acid 
NIH  = National Institute of Health 
nM  = nanomolar 
nm  = nanometer 
NTC  = no template control 
OECD  = Organization for Economic Cooperation Development 
PBS  = phosphate-buffered saline 
PCR  = polymerase chain reaction 
pH  = potential of hydrogen 
′ (prime) = denotes a truncated gene at the indicated side 
PRL  = prolactin 
qRT-PCR = quantitative TaqManReal-time PCR 
RIA  = radioimmunoassay 
RNA  = ribonucleic acid 
RNase  = ribonuclease 
RNasin = ribonuclease inhibitor 
rpm  = round per minute 
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SEM  = standard of the mean 
sec  = second 
s.c.  = subcutaneous 
STDN  = standard  
T  = testosterone 
TAMRA = 6-carboxy-tetramethyl-rhodamine 
Taq  = Thermus  aquaticus DNA polymerase 
TERP-1 = truncated estrogen receptor product-1 
TERP-2 = truncated estrogen receptor product-2 
TGs  = triglycerides 
TSHβ  = beta subunit of thyroid-stimulating hormone 
T3  = triiodothyronine 
T4  = tetraiodothyronine or thyroxine 
U  = unit 
UNG  = uracil-N-glycocylase 
UNKN  = unknown 
U.S. EPA = United States Environmental Protection Agency 
UV  = ultraviolet 
VZ  = vinclozolin 
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